drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.71k
| drug2_id
int64 1
1.71k
| drug1_name
stringlengths 4
31
| drug2_name
stringlengths 4
31
| drug1_desc
stringlengths 27
1.09k
⌀ | drug2_desc
stringlengths 27
1.06k
⌀ | label
stringlengths 58
191
| label_idx
int64 0
85
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
2.58k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01440
|
DB06144
| 974 | 257 |
gamma-Hydroxybutyric acid
|
Sertindole
|
Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.
|
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.
|
The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Sertindole.
| 48 |
[
[
[
974,
71,
257
]
],
[
[
974,
225,
413
],
[
413,
1,
257
]
],
[
[
974,
71,
142
],
[
142,
26,
257
]
],
[
[
974,
225,
156
],
[
156,
26,
257
]
],
[
[
974,
192,
679
],
[
679,
38,
257
]
],
[
[
974,
38,
405
],
[
405,
192,
257
]
],
[
[
974,
54,
1046
],
[
1046,
208,
257
]
],
[
[
974,
71,
18
],
[
18,
58,
257
]
],
[
[
974,
71,
200
],
[
200,
223,
257
]
],
[
[
974,
225,
288
],
[
288,
223,
257
]
]
] |
[
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} (Compound) resembles {v} (Compound)",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the antipsychotic activities of {v}",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may decrease the metabolism of {v}",
"Sertindole"
]
],
[
[
"gamma-Hydroxybutyric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Promazine"
],
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Sertindole"
]
]
] |
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Pimozide and Pimozide (Compound) resembles Sertindole (Compound)
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Phenytoin and Phenytoin can increase the metabolism of Sertindole
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Sertindole
gamma-Hydroxybutyric acid may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Sertindole
gamma-Hydroxybutyric acid may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Sertindole
gamma-Hydroxybutyric acid may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Sertindole
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the antipsychotic activities of Sertindole
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Cocaine and Cocaine may decrease the metabolism of Sertindole
gamma-Hydroxybutyric acid may increase the severity of adverse effects when combined with Promazine and Promazine may decrease the metabolism of Sertindole
|
DB00679
|
DB09274
| 653 | 1,075 |
Thioridazine
|
Artesunate
|
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
|
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
|
The serum concentration of Artesunate can be increased when it is combined with Thioridazine.
| 72 |
[
[
[
653,
95,
1075
]
],
[
[
653,
95,
514
],
[
514,
33,
1075
]
],
[
[
653,
42,
1097
],
[
1097,
33,
1075
]
],
[
[
653,
71,
164
],
[
164,
33,
1075
]
],
[
[
653,
225,
435
],
[
435,
33,
1075
]
],
[
[
653,
95,
539
],
[
539,
209,
1075
]
],
[
[
653,
95,
495
],
[
495,
55,
1075
]
],
[
[
653,
155,
1379
],
[
1379,
95,
1075
]
],
[
[
653,
1,
964
],
[
964,
95,
1075
]
],
[
[
653,
95,
392
],
[
392,
95,
1075
]
]
] |
[
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} may increase the QTc prolonging activities of {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nilvadipine"
],
[
"Nilvadipine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Periciazine"
],
[
"Periciazine",
"{u} may increase the serum concentration of {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Triflupromazine"
],
[
"Triflupromazine",
"{u} may increase the serum concentration of {v}",
"Artesunate"
]
],
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may increase the serum concentration of {v}",
"Artesunate"
]
]
] |
Thioridazine may increase the serum concentration of Rosiglitazone and Rosiglitazone may reduce the serum concentration of the active metabolites of Artesunate
Thioridazine may increase the QTc prolonging activities of Ezogabine and Ezogabine may reduce the serum concentration of the active metabolites of Artesunate
Thioridazine may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital may reduce the serum concentration of the active metabolites of Artesunate
Thioridazine may increase the severity of adverse effects when combined with Nilvadipine and Nilvadipine may reduce the serum concentration of the active metabolites of Artesunate
Thioridazine may increase the serum concentration of Artemether and Artemether may increase the severity of QTc prolonging effects when combined with Artesunate
Thioridazine may increase the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Artesunate
Thioridazine (Compound) resembles Periciazine (Compound) and Periciazine may increase the serum concentration of Artesunate
Thioridazine (Compound) resembles Triflupromazine (Compound) and Triflupromazine may increase the serum concentration of Artesunate
Thioridazine may increase the serum concentration of Chlorpromazine and Chlorpromazine may increase the serum concentration of Artesunate
|
DB00706
|
DB01054
| 509 | 329 |
Tamsulosin
|
Nitrendipine
|
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension. Tamsulosin was first approved by the FDA on April 15, 1997.
|
Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
|
Tamsulosin may increase the hypotensive activities of Nitrendipine.
| 59 |
[
[
[
509,
82,
329
]
],
[
[
509,
69,
472
],
[
472,
223,
329
]
],
[
[
509,
82,
435
],
[
435,
1,
329
]
],
[
[
509,
69,
158
],
[
158,
1,
329
]
],
[
[
509,
6,
4590
],
[
4590,
160,
329
]
],
[
[
509,
180,
164
],
[
164,
26,
329
]
],
[
[
509,
236,
197
],
[
197,
26,
329
]
],
[
[
509,
236,
344
],
[
344,
32,
329
]
],
[
[
509,
95,
1092
],
[
1092,
223,
329
]
],
[
[
509,
71,
679
],
[
679,
225,
329
]
]
] |
[
[
[
"Tamsulosin",
"{u} may increase the hypotensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} may decrease the metabolism of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may decrease the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} may increase the hypotensive activities of {v}",
"Nilvadipine"
],
[
"Nilvadipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} may increase the hypotensive activities of {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} can increase the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} may increase the hypotensive activities of {v}",
"Udenafil"
],
[
"Udenafil",
"{u} may increase the antihypertensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} may increase the serum concentration of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may decrease the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Tamsulosin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrendipine"
]
]
] |
Tamsulosin may decrease the metabolism of Isradipine and Isradipine may decrease the metabolism of Nitrendipine
Tamsulosin may increase the hypotensive activities of Nilvadipine and Nilvadipine (Compound) resembles Nitrendipine (Compound)
Tamsulosin may decrease the metabolism of Nicardipine and Nicardipine (Compound) resembles Nitrendipine (Compound)
Tamsulosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nitrendipine (Compound)
Tamsulosin can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Nitrendipine
Tamsulosin may increase the hypotensive activities of Amobarbital and Amobarbital can increase the metabolism of Nitrendipine
Tamsulosin may increase the hypotensive activities of Udenafil and Udenafil may increase the antihypertensive activities of Nitrendipine
Tamsulosin may increase the serum concentration of Telaprevir and Telaprevir may decrease the metabolism of Nitrendipine
Tamsulosin may increase the severity of adverse effects when combined with Thalidomide and Thalidomide may increase the severity of adverse effects when combined with Nitrendipine
|
DB00648
|
DB06786
| 1,080 | 122 |
Mitotane
|
Halcinonide
|
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
|
Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide.
|
The serum concentration of Halcinonide can be decreased when it is combined with Mitotane.
| 74 |
[
[
[
1080,
97,
122
]
],
[
[
1080,
97,
478
],
[
478,
71,
122
]
],
[
[
1080,
97,
209
],
[
209,
225,
122
]
],
[
[
1080,
97,
1019
],
[
1019,
92,
122
]
],
[
[
1080,
97,
479
],
[
479,
249,
122
]
],
[
[
1080,
97,
142
],
[
142,
97,
122
]
],
[
[
1080,
97,
1092
],
[
1092,
251,
122
]
],
[
[
1080,
97,
1324
],
[
1324,
100,
122
]
],
[
[
1080,
97,
183
],
[
183,
259,
122
]
],
[
[
1080,
97,
478
],
[
478,
71,
449
],
[
449,
71,
122
]
]
] |
[
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Olopatadine"
],
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may decrease the therapeutic efficacy of {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may increase the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may decrease the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the hyperglycemic activities of {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may increase the hypokalemic activities of {v}",
"Halcinonide"
]
],
[
[
"Mitotane",
"{u} may decrease the serum concentration of {v}",
"Olopatadine"
],
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
],
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
]
] |
Mitotane may decrease the serum concentration of Olopatadine and Olopatadine may increase the severity of adverse effects when combined with Halcinonide
Mitotane may decrease the serum concentration of Donepezil and Donepezil may increase the severity of adverse effects when combined with Halcinonide
Mitotane may decrease the serum concentration of Mifepristone and Mifepristone may decrease the therapeutic efficacy of Halcinonide
Mitotane may decrease the serum concentration of Posaconazole and Posaconazole may increase the serum concentration of Halcinonide
Mitotane may decrease the serum concentration of Phenytoin and Phenytoin may decrease the serum concentration of Halcinonide
Mitotane may decrease the serum concentration of Telaprevir and Telaprevir may decrease the serum concentration of Halcinonide
Mitotane may decrease the serum concentration of Ceritinib and Ceritinib may increase the hyperglycemic activities of Halcinonide
Mitotane may decrease the serum concentration of Indapamide and Indapamide may increase the hypokalemic activities of Halcinonide
Mitotane may decrease the serum concentration of Olopatadine and Olopatadine may increase the severity of adverse effects when combined with Tolfenamic acid and Tolfenamic acid may increase the severity of adverse effects when combined with Halcinonide
|
DB00950
|
DB00653
| 959 | 405 |
Fexofenadine
|
Magnesium sulfate
|
Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of [terfenadine] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.
|
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
|
Fexofenadine may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate.
| 15 |
[
[
[
959,
38,
405
]
],
[
[
959,
21,
28733
],
[
28733,
175,
405
]
],
[
[
959,
225,
977
],
[
977,
38,
405
]
],
[
[
959,
71,
1097
],
[
1097,
38,
405
]
],
[
[
959,
38,
1262
],
[
1262,
192,
405
]
],
[
[
959,
270,
954
],
[
954,
38,
405
]
],
[
[
959,
184,
674
],
[
674,
38,
405
]
],
[
[
959,
192,
1083
],
[
1083,
38,
405
]
],
[
[
959,
38,
1265
],
[
1265,
38,
405
]
],
[
[
959,
54,
1046
],
[
1046,
208,
405
]
]
] |
[
[
[
"Fexofenadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} (Compound) causes {v} (Side Effect)",
"Flushing"
],
[
"Flushing",
"{u} (Side Effect) is caused by {v} (Compound)",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
],
[
"Fluspirilene",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Fexofenadine",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Magnesium sulfate"
]
]
] |
Fexofenadine (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Magnesium sulfate (Compound)
Fexofenadine may increase the severity of adverse effects when combined with Butalbital and Butalbital may increase the central nervous system depressant activities of Magnesium sulfate
Fexofenadine may increase the severity of adverse effects when combined with Ezogabine and Ezogabine may increase the central nervous system depressant activities of Magnesium sulfate
Fexofenadine may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Magnesium sulfate
Fexofenadine (Compound) resembles Fluspirilene (Compound) and Fexofenadine may increase the severity of adverse effects when combined with Fluspirilene and Fluspirilene may increase the central nervous system depressant activities of Magnesium sulfate
Fexofenadine can increase the therapeutic efficacy of Pregabalin and Pregabalin may increase the central nervous system depressant activities of Magnesium sulfate
Fexofenadine may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Magnesium sulfate
Fexofenadine may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Magnesium sulfate
Fexofenadine may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Magnesium sulfate
|
DB00961
|
DB09017
| 962 | 930 |
Mepivacaine
|
Brotizolam
|
A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
|
Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours). Brotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.
|
The risk or severity of adverse effects can be increased when Mepivacaine is combined with Brotizolam.
| 48 |
[
[
[
962,
71,
930
]
],
[
[
962,
184,
674
],
[
674,
30,
930
]
],
[
[
962,
192,
679
],
[
679,
38,
930
]
],
[
[
962,
38,
1265
],
[
1265,
192,
930
]
],
[
[
962,
54,
471
],
[
471,
208,
930
]
],
[
[
962,
225,
994
],
[
994,
71,
930
]
],
[
[
962,
71,
976
],
[
976,
225,
930
]
],
[
[
962,
71,
973
],
[
973,
71,
930
]
],
[
[
962,
95,
911
],
[
911,
71,
930
]
],
[
[
962,
116,
214
],
[
214,
71,
930
]
]
] |
[
[
[
"Mepivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butabarbital"
],
[
"Butabarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dimenhydrinate"
],
[
"Dimenhydrinate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} may increase the serum concentration of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Mepivacaine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
],
[
"Levobupivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
]
] |
Mepivacaine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Brotizolam
Mepivacaine may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Brotizolam
Mepivacaine may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Brotizolam
Mepivacaine may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Brotizolam
Mepivacaine may increase the severity of adverse effects when combined with Butabarbital and Butabarbital may increase the severity of adverse effects when combined with Brotizolam
Mepivacaine may increase the severity of adverse effects when combined with Dimenhydrinate and Dimenhydrinate may increase the severity of adverse effects when combined with Brotizolam
Mepivacaine may increase the severity of adverse effects when combined with Aceprometazine and Aceprometazine may increase the severity of adverse effects when combined with Brotizolam
Mepivacaine may increase the serum concentration of Oxprenolol and Oxprenolol may increase the severity of adverse effects when combined with Brotizolam
Mepivacaine (Compound) resembles Levobupivacaine (Compound) and Mepivacaine may increase the severity of adverse effects when combined with Levobupivacaine and Levobupivacaine may increase the severity of adverse effects when combined with Brotizolam
|
DB01041
|
DB01356
| 679 | 997 |
Thalidomide
|
Lithium cation
|
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
|
Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
|
Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Lithium cation.
| 15 |
[
[
[
679,
38,
997
]
],
[
[
679,
21,
28392
],
[
28392,
175,
997
]
],
[
[
679,
192,
72
],
[
72,
38,
997
]
],
[
[
679,
38,
1264
],
[
1264,
192,
997
]
],
[
[
679,
71,
1027
],
[
1027,
42,
997
]
],
[
[
679,
69,
645
],
[
645,
42,
997
]
],
[
[
679,
95,
1324
],
[
1324,
42,
997
]
],
[
[
679,
54,
1365
],
[
1365,
208,
997
]
],
[
[
679,
95,
495
],
[
495,
55,
997
]
],
[
[
679,
38,
940
],
[
940,
211,
997
]
]
] |
[
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} may decrease the metabolism of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the QTc prolonging activities of {v}",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Lithium cation"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
]
]
] |
Thalidomide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Lithium cation (Compound)
Thalidomide may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Lithium cation
Thalidomide may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Lithium cation
Thalidomide may increase the severity of adverse effects when combined with Sotalol and Sotalol may increase the QTc prolonging activities of Lithium cation
Thalidomide may decrease the metabolism of Azithromycin and Azithromycin may increase the QTc prolonging activities of Lithium cation
Thalidomide may increase the serum concentration of Ceritinib and Ceritinib may increase the QTc prolonging activities of Lithium cation
Thalidomide may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Lithium cation
Thalidomide may increase the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Lithium cation
Thalidomide may increase the central nervous system depressant activities of Trifluoperazine and Trifluoperazine may increase the neurotoxic activities of Lithium cation
|
DB01192
|
DB00384
| 327 | 1,359 |
Oxymorphone
|
Triamterene
|
An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
|
Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various
|
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Triamterene.
| 48 |
[
[
[
327,
71,
1359
]
],
[
[
327,
21,
28613
],
[
28613,
175,
1359
]
],
[
[
327,
71,
968
],
[
968,
206,
1359
]
],
[
[
327,
69,
588
],
[
588,
213,
1359
]
],
[
[
327,
71,
478
],
[
478,
213,
1359
]
],
[
[
327,
69,
198
],
[
198,
218,
1359
]
],
[
[
327,
69,
613
],
[
613,
223,
1359
]
],
[
[
327,
71,
611
],
[
611,
223,
1359
]
],
[
[
327,
71,
724
],
[
724,
225,
1359
]
],
[
[
327,
225,
934
],
[
934,
71,
1359
]
]
] |
[
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} may decrease the metabolism of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may decrease the antihypertensive activities of {v}",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olopatadine"
],
[
"Olopatadine",
"{u} may decrease the antihypertensive activities of {v}",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} may decrease the metabolism of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the severity of hyperkalemic effects when combined with {v}",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexmedetomidine"
],
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triamterene"
]
],
[
[
"Oxymorphone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Remifentanil"
],
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triamterene"
]
]
] |
Oxymorphone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Triamterene (Compound)
Oxymorphone may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Triamterene
Oxymorphone may decrease the metabolism of Chloroquine and Chloroquine may decrease the antihypertensive activities of Triamterene
Oxymorphone may increase the severity of adverse effects when combined with Olopatadine and Olopatadine may decrease the antihypertensive activities of Triamterene
Oxymorphone may decrease the metabolism of Cyclosporine and Cyclosporine may increase the severity of hyperkalemic effects when combined with Triamterene
Oxymorphone may decrease the metabolism of Ticlopidine and Ticlopidine may decrease the metabolism of Triamterene
Oxymorphone may increase the severity of adverse effects when combined with Lidocaine and Lidocaine may decrease the metabolism of Triamterene
Oxymorphone may increase the severity of adverse effects when combined with Dexmedetomidine and Dexmedetomidine may increase the severity of adverse effects when combined with Triamterene
Oxymorphone may increase the severity of adverse effects when combined with Remifentanil and Remifentanil may increase the severity of adverse effects when combined with Triamterene
|
DB09232
|
DB01144
| 605 | 1,357 |
Cilnidipine
|
Diclofenamide
|
Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium antagonists. This drug is approved in China, Japan, Korea, India, and several countries in the European Union.
|
A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
|
The risk or severity of adverse effects can be increased when Cilnidipine is combined with Diclofenamide.
| 48 |
[
[
[
605,
71,
1357
]
],
[
[
605,
71,
1048
],
[
1048,
71,
1357
]
],
[
[
605,
52,
968
],
[
968,
206,
1357
]
],
[
[
605,
71,
45
],
[
45,
225,
1357
]
],
[
[
605,
225,
1151
],
[
1151,
71,
1357
]
],
[
[
605,
82,
1050
],
[
1050,
71,
1357
]
],
[
[
605,
236,
678
],
[
678,
71,
1357
]
],
[
[
605,
249,
142
],
[
142,
225,
1357
]
],
[
[
605,
180,
171
],
[
171,
82,
1357
]
],
[
[
605,
82,
453
],
[
453,
236,
1357
]
]
] |
[
[
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} may increase the hypotensive activities of {v}",
"Nitroprusside"
],
[
"Nitroprusside",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} may increase the hypotensive activities of {v}",
"Doxazosin"
],
[
"Doxazosin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} may increase the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may increase the hypotensive activities of {v}",
"Diclofenamide"
]
],
[
[
"Cilnidipine",
"{u} may increase the hypotensive activities of {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may increase the hypotensive activities of {v}",
"Diclofenamide"
]
]
] |
Cilnidipine may increase the severity of adverse effects when combined with Chlorothiazide and Chlorothiazide may increase the severity of adverse effects when combined with Diclofenamide
Cilnidipine may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Diclofenamide
Cilnidipine may increase the severity of adverse effects when combined with Mecamylamine and Mecamylamine may increase the severity of adverse effects when combined with Diclofenamide
Cilnidipine may increase the severity of adverse effects when combined with Amphotericin B and Amphotericin B may increase the severity of adverse effects when combined with Diclofenamide
Cilnidipine may increase the hypotensive activities of Nitroprusside and Nitroprusside may increase the severity of adverse effects when combined with Diclofenamide
Cilnidipine may increase the hypotensive activities of Doxazosin and Doxazosin may increase the severity of adverse effects when combined with Diclofenamide
Cilnidipine may increase the serum concentration of Phenytoin and Phenytoin may increase the severity of adverse effects when combined with Diclofenamide
Cilnidipine can increase the metabolism of Pentobarbital and Pentobarbital may increase the hypotensive activities of Diclofenamide
Cilnidipine may increase the hypotensive activities of Risperidone and Risperidone may increase the hypotensive activities of Diclofenamide
|
DB00401
|
DB01601
| 512 | 429 |
Nisoldipine
|
Lopinavir
|
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
|
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the
|
The metabolism of Lopinavir can be decreased when combined with Nisoldipine.
| 46 |
[
[
[
512,
128,
429
]
],
[
[
512,
128,
564
],
[
564,
155,
429
]
],
[
[
512,
6,
8339
],
[
8339,
160,
429
]
],
[
[
512,
288,
161
],
[
161,
26,
429
]
],
[
[
512,
251,
171
],
[
171,
26,
429
]
],
[
[
512,
225,
430
],
[
430,
180,
429
]
],
[
[
512,
59,
274
],
[
274,
180,
429
]
],
[
[
512,
236,
194
],
[
194,
180,
429
]
],
[
[
512,
249,
730
],
[
730,
196,
429
]
],
[
[
512,
97,
59
],
[
59,
42,
429
]
]
] |
[
[
[
"Nisoldipine",
"{u} may decrease the metabolism of {v} and {u} may increase the serum concentration of {v}",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} may decrease the metabolism of {v} and {u} may increase the serum concentration of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} can increase the metabolism of {v} and {u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} may decrease the serum concentration of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxiconazole"
],
[
"Oxiconazole",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} may decrease the antihypertensive activities of {v}",
"Melatonin"
],
[
"Melatonin",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} may increase the hypotensive activities of {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} can increase the metabolism of {v}",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} may increase the serum concentration of {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
],
[
[
"Nisoldipine",
"{u} may decrease the serum concentration of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the QTc prolonging activities of {v}",
"Lopinavir"
]
]
] |
and Nisoldipine may increase the serum concentration of Lopinavir
Nisoldipine may decrease the metabolism of Atazanavir and Nisoldipine may increase the serum concentration of Atazanavir and Atazanavir (Compound) resembles Lopinavir (Compound)
Nisoldipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lopinavir (Compound)
Nisoldipine can increase the metabolism of Primidone and Nisoldipine may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Lopinavir
Nisoldipine may decrease the serum concentration of Pentobarbital and Pentobarbital can increase the metabolism of Lopinavir
Nisoldipine may increase the severity of adverse effects when combined with Oxiconazole and Oxiconazole can increase the metabolism of Lopinavir
Nisoldipine may decrease the antihypertensive activities of Melatonin and Melatonin can increase the metabolism of Lopinavir
Nisoldipine may increase the hypotensive activities of Methylphenobarbital and Methylphenobarbital can increase the metabolism of Lopinavir
Nisoldipine may increase the serum concentration of Tizanidine and Tizanidine may increase the QTc prolonging activities of Lopinavir
Nisoldipine may decrease the serum concentration of Quinidine and Quinidine may increase the QTc prolonging activities of Lopinavir
|
DB01041
|
DB00752
| 679 | 63 |
Thalidomide
|
Tranylcypromine
|
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
|
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
|
Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
| 15 |
[
[
[
679,
38,
63
]
],
[
[
679,
38,
915
],
[
915,
225,
63
]
],
[
[
679,
225,
53
],
[
53,
225,
63
]
],
[
[
679,
38,
151
],
[
151,
69,
63
]
],
[
[
679,
6,
12128
],
[
12128,
160,
63
]
],
[
[
679,
21,
28462
],
[
28462,
175,
63
]
],
[
[
679,
38,
41
],
[
41,
24,
63
]
],
[
[
679,
184,
674
],
[
674,
30,
63
]
],
[
[
679,
71,
953
],
[
953,
31,
63
]
],
[
[
679,
95,
1019
],
[
1019,
31,
63
]
]
] |
[
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Fencamfamin"
],
[
"Fencamfamin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Benzyl alcohol"
],
[
"Benzyl alcohol",
"{u} may decrease the metabolism of {v}",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the anticholinergic activities of {v}",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Tranylcypromine"
]
],
[
[
"Thalidomide",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the hypoglycemic activities of {v}",
"Tranylcypromine"
]
]
] |
Thalidomide may increase the central nervous system depressant activities of Fencamfamin and Fencamfamin may increase the severity of adverse effects when combined with Tranylcypromine
Thalidomide may increase the severity of adverse effects when combined with Phenelzine and Phenelzine may increase the severity of adverse effects when combined with Tranylcypromine
Thalidomide may increase the central nervous system depressant activities of Benzyl alcohol and Benzyl alcohol may decrease the metabolism of Tranylcypromine
Thalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tranylcypromine (Compound)
Thalidomide (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Tranylcypromine (Compound)
Thalidomide may increase the central nervous system depressant activities of Clemastine and Clemastine may increase the anticholinergic activities of Tranylcypromine
Thalidomide can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Tranylcypromine
Thalidomide may increase the severity of adverse effects when combined with Empagliflozin and Empagliflozin may increase the hypoglycemic activities of Tranylcypromine
Thalidomide may increase the serum concentration of Mifepristone and Mifepristone may increase the hypoglycemic activities of Tranylcypromine
|
DB00542
|
DB01244
| 642 | 190 |
Benazepril
|
Bepridil
|
Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
|
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
|
Benazepril may increase the hypotensive activities of Bepridil.
| 59 |
[
[
[
642,
82,
190
]
],
[
[
642,
236,
17
],
[
17,
82,
190
]
],
[
[
642,
82,
355
],
[
355,
82,
190
]
],
[
[
642,
155,
16890
],
[
16890,
155,
190
]
],
[
[
642,
155,
961
],
[
961,
1,
190
]
],
[
[
642,
5,
17090
],
[
17090,
159,
190
]
],
[
[
642,
21,
28770
],
[
28770,
175,
190
]
],
[
[
642,
236,
197
],
[
197,
26,
190
]
],
[
[
642,
186,
702
],
[
702,
32,
190
]
],
[
[
642,
249,
615
],
[
615,
32,
190
]
]
] |
[
[
[
"Benazepril",
"{u} may increase the hypotensive activities of {v}",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} may increase the hypotensive activities of {v}",
"Trimethaphan"
],
[
"Trimethaphan",
"{u} may increase the hypotensive activities of {v}",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} may increase the hypotensive activities of {v}",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} may increase the hypotensive activities of {v}",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} (Compound) resembles {v} (Compound)",
"Benzyl Benzoate"
],
[
"Benzyl Benzoate",
"{u} (Compound) resembles {v} (Compound)",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} may increase the hypotensive activities of {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} can increase the metabolism of {v}",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} may increase the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Bepridil"
]
],
[
[
"Benazepril",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Bepridil"
]
]
] |
Benazepril may increase the hypotensive activities of Trimethaphan and Trimethaphan may increase the hypotensive activities of Bepridil
Benazepril may increase the hypotensive activities of Phenoxybenzamine and Phenoxybenzamine may increase the hypotensive activities of Bepridil
Benazepril (Compound) resembles Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) resembles Bepridil (Compound)
Benazepril (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) resembles Bepridil (Compound)
Benazepril (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Bepridil (Compound)
Benazepril (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Bepridil (Compound)
Benazepril may increase the hypotensive activities of Amobarbital and Amobarbital can increase the metabolism of Bepridil
Benazepril may increase the antihypertensive activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Bepridil
Benazepril may increase the serum concentration of Sildenafil and Sildenafil may increase the antihypertensive activities of Bepridil
|
DB01174
|
DB00850
| 164 | 525 |
Phenobarbital
|
Perphenazine
|
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
|
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
|
The metabolism of Perphenazine can be increased when combined with Phenobarbital.
| 3 |
[
[
[
164,
26,
525
]
],
[
[
164,
97,
971
],
[
971,
225,
525
]
],
[
[
164,
26,
370
],
[
370,
155,
525
]
],
[
[
164,
26,
270
],
[
270,
71,
525
]
],
[
[
164,
71,
964
],
[
964,
155,
525
]
],
[
[
164,
225,
940
],
[
940,
71,
525
]
],
[
[
164,
71,
970
],
[
970,
1,
525
]
],
[
[
164,
225,
653
],
[
653,
95,
525
]
],
[
[
164,
6,
10999
],
[
10999,
160,
525
]
],
[
[
164,
21,
28387
],
[
28387,
175,
525
]
]
] |
[
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} may decrease the serum concentration of {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Domperidone"
],
[
"Domperidone",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triflupromazine"
],
[
"Triflupromazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiothixene"
],
[
"Thiothixene",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Phenobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Perphenazine"
]
]
] |
Phenobarbital may decrease the serum concentration of Zuclopenthixol and Zuclopenthixol may increase the severity of adverse effects when combined with Perphenazine
Phenobarbital can increase the metabolism of Domperidone and Domperidone (Compound) resembles Perphenazine (Compound)
Phenobarbital can increase the metabolism of Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Perphenazine
Phenobarbital may increase the severity of adverse effects when combined with Triflupromazine and Triflupromazine (Compound) resembles Perphenazine (Compound)
Phenobarbital may increase the severity of adverse effects when combined with Trifluoperazine and Trifluoperazine may increase the severity of adverse effects when combined with Perphenazine
Phenobarbital may increase the severity of adverse effects when combined with Thiothixene and Thiothixene (Compound) resembles Perphenazine (Compound)
Phenobarbital may increase the severity of adverse effects when combined with Thioridazine and Thioridazine may increase the serum concentration of Perphenazine
Phenobarbital (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Perphenazine (Compound)
Phenobarbital (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Perphenazine (Compound)
|
DB00937
|
DB06723
| 1,334 | 88 |
Diethylpropion
|
Aluminum hydroxide
|
A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
|
Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
|
Diethylpropion may decrease the excretion rate of Aluminum hydroxide which could result in a higher serum level.
| 71 |
[
[
[
1334,
94,
88
]
],
[
[
1334,
251,
1299
],
[
1299,
40,
88
]
],
[
[
1334,
83,
973
],
[
973,
89,
88
]
],
[
[
1334,
94,
78
],
[
78,
246,
88
]
],
[
[
1334,
251,
1506
],
[
1506,
246,
88
]
],
[
[
1334,
98,
959
],
[
959,
251,
88
]
],
[
[
1334,
251,
1299
],
[
1299,
249,
124
],
[
124,
179,
88
]
],
[
[
1334,
83,
973
],
[
973,
155,
653
],
[
653,
89,
88
]
],
[
[
1334,
83,
270
],
[
270,
21,
28379
],
[
28379,
175,
88
]
],
[
[
1334,
83,
288
],
[
288,
249,
653
],
[
653,
89,
88
]
]
] |
[
[
[
"Diethylpropion",
"{u} may decrease the excretion rate {v}",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the serum concentration of {v}",
"Ascorbic acid"
],
[
"Ascorbic acid",
"{u} can increase the absorption and serum concentration of {v}",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the excretion rate {v}",
"Bismuth subcitrate potassium"
],
[
"Bismuth subcitrate potassium",
"{u} may decrease the therapeutic efficacy of {v}",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the serum concentration of {v}",
"Methenamine"
],
[
"Methenamine",
"{u} may decrease the therapeutic efficacy of {v}",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the sedative activities of {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may decrease the serum concentration of {v}",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the serum concentration of {v}",
"Ascorbic acid"
],
[
"Ascorbic acid",
"{u} may increase the serum concentration of {v}",
"Estrone"
],
[
"Estrone",
"{u} can decrease the bioavailability of {v}",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aluminum hydroxide"
]
],
[
[
"Diethylpropion",
"{u} may decrease the stimulatory activities of {v}",
"Promazine"
],
[
"Promazine",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Aluminum hydroxide"
]
]
] |
Diethylpropion may decrease the serum concentration of Ascorbic acid and Ascorbic acid can increase the absorption and serum concentration of Aluminum hydroxide
Diethylpropion may decrease the stimulatory activities of Aceprometazine and Aceprometazine may decrease the absorption and serum concentration of Aluminum hydroxide
Diethylpropion may decrease the excretion rate Bismuth subcitrate potassium and Bismuth subcitrate potassium may decrease the therapeutic efficacy of Aluminum hydroxide
Diethylpropion may decrease the serum concentration of Methenamine and Methenamine may decrease the therapeutic efficacy of Aluminum hydroxide
Diethylpropion may decrease the sedative activities of Fexofenadine and Fexofenadine may decrease the serum concentration of Aluminum hydroxide
Diethylpropion may decrease the serum concentration of Ascorbic acid and Ascorbic acid may increase the serum concentration of Estrone and Estrone can decrease the bioavailability of Aluminum hydroxide
Diethylpropion may decrease the stimulatory activities of Aceprometazine and Aceprometazine (Compound) resembles Thioridazine (Compound) and Thioridazine may decrease the absorption and serum concentration of Aluminum hydroxide
Diethylpropion may decrease the stimulatory activities of Prochlorperazine and Prochlorperazine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Diethylpropion may decrease the stimulatory activities of Promazine and Promazine may increase the serum concentration of Thioridazine and Thioridazine may decrease the absorption and serum concentration of Aluminum hydroxide
|
DB00503
|
DB01072
| 244 | 564 |
Ritonavir
|
Atazanavir
|
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
|
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
|
The serum concentration of Atazanavir can be increased when it is combined with Ritonavir.
| 72 |
[
[
[
244,
119,
564
]
],
[
[
244,
69,
429
],
[
429,
1,
564
]
],
[
[
244,
6,
8339
],
[
8339,
160,
564
]
],
[
[
244,
169,
24775
],
[
24775,
15,
564
]
],
[
[
244,
21,
28747
],
[
28747,
175,
564
]
],
[
[
244,
251,
150
],
[
150,
26,
564
]
],
[
[
244,
180,
161
],
[
161,
26,
564
]
],
[
[
244,
196,
1007
],
[
1007,
42,
564
]
],
[
[
244,
223,
209
],
[
209,
69,
564
]
],
[
[
244,
249,
1084
],
[
1084,
69,
564
]
]
] |
[
[
[
"Ritonavir",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Cytochrome P450 3A Inhibitors"
],
[
"Cytochrome P450 3A Inhibitors",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} may decrease the metabolism of {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Ritonavir",
"{u} may increase the serum concentration of {v}",
"Itraconazole"
],
[
"Itraconazole",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
]
]
] |
Ritonavir (Compound) resembles Atazanavir (Compound) and
Ritonavir may decrease the metabolism of Lopinavir and Lopinavir (Compound) resembles Atazanavir (Compound)
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Ritonavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class) and Cytochrome P450 3A Inhibitors (Pharmacologic Class) includes Atazanavir (Compound)
Ritonavir (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Atazanavir (Compound)
Ritonavir may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Atazanavir
Ritonavir can increase the metabolism of Primidone and Primidone can increase the metabolism of Atazanavir
Ritonavir may increase the QTc prolonging activities of Paliperidone and Paliperidone may increase the QTc prolonging activities of Atazanavir
Ritonavir may decrease the metabolism of Donepezil and Donepezil may decrease the metabolism of Atazanavir
Ritonavir may increase the serum concentration of Itraconazole and Itraconazole may decrease the metabolism of Atazanavir
|
DB06603
|
DB01211
| 1,098 | 1,088 |
Panobinostat
|
Clarithromycin
|
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
|
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
|
The serum concentration of Clarithromycin can be increased when it is combined with Panobinostat.
| 72 |
[
[
[
1098,
95,
1088
]
],
[
[
1098,
104,
383
],
[
383,
196,
1088
]
],
[
[
1098,
42,
689
],
[
689,
196,
1088
]
],
[
[
1098,
196,
1317
],
[
1317,
42,
1088
]
],
[
[
1098,
249,
956
],
[
956,
42,
1088
]
],
[
[
1098,
249,
1293
],
[
1293,
196,
1088
]
],
[
[
1098,
95,
429
],
[
429,
42,
1088
]
],
[
[
1098,
249,
26
],
[
26,
69,
1088
]
],
[
[
1098,
42,
183
],
[
183,
69,
1088
]
],
[
[
1098,
196,
1185
],
[
1185,
69,
1088
]
]
] |
[
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the arrhythmogenic activities of {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may increase the QTc prolonging activities of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may increase the QTc prolonging activities of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} may increase the QTc prolonging activities of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may increase the QTc prolonging activities of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may decrease the metabolism of {v}",
"Clarithromycin"
]
],
[
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may decrease the metabolism of {v}",
"Clarithromycin"
]
]
] |
Panobinostat may increase the arrhythmogenic activities of Granisetron and Granisetron may increase the QTc prolonging activities of Clarithromycin
Panobinostat may increase the QTc prolonging activities of Treprostinil and Treprostinil may increase the QTc prolonging activities of Clarithromycin
Panobinostat may increase the QTc prolonging activities of Ibutilide and Ibutilide may increase the QTc prolonging activities of Clarithromycin
Panobinostat may increase the serum concentration of Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Clarithromycin
Panobinostat may increase the serum concentration of Metoclopramide and Metoclopramide may increase the QTc prolonging activities of Clarithromycin
Panobinostat may increase the serum concentration of Lopinavir and Lopinavir may increase the QTc prolonging activities of Clarithromycin
Panobinostat may increase the serum concentration of Tiotropium and Tiotropium may decrease the metabolism of Clarithromycin
Panobinostat may increase the QTc prolonging activities of Indapamide and Indapamide may decrease the metabolism of Clarithromycin
Panobinostat may increase the QTc prolonging activities of Vandetanib and Vandetanib may decrease the metabolism of Clarithromycin
|
DB00258
|
DB01077
| 1,454 | 1,342 |
Calcium acetate
|
Etidronic acid
|
The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form.
|
Etidronic acid is a first generation bisphosphonate similar to [clodronic acid] and [tiludronic acid]. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]. Etidronic acid was granted FDA approval on 1 September 1977.
|
The serum concentration of Etidronic acid can be decreased when it is combined with Calcium acetate.
| 74 |
[
[
[
1454,
97,
1342
]
],
[
[
1454,
97,
1320
],
[
1320,
155,
1342
]
],
[
[
1454,
97,
1343
],
[
1343,
1,
1342
]
],
[
[
1454,
5,
18213
],
[
18213,
159,
1342
]
],
[
[
1454,
21,
28671
],
[
28671,
175,
1342
]
],
[
[
1454,
92,
449
],
[
449,
71,
1342
]
],
[
[
1454,
225,
1512
],
[
1512,
97,
1342
]
],
[
[
1454,
97,
1320
],
[
1320,
155,
1338
],
[
1338,
155,
1342
]
],
[
[
1454,
97,
1341
],
[
1341,
1,
1320
],
[
1320,
155,
1342
]
],
[
[
1454,
5,
18213
],
[
18213,
159,
1320
],
[
1320,
155,
1342
]
]
] |
[
[
[
"Calcium acetate",
"{u} may decrease the serum concentration of {v}",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} may decrease the serum concentration of {v}",
"Ibandronate"
],
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} may decrease the serum concentration of {v}",
"Clodronic acid"
],
[
"Clodronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) treats {v} (Disease)",
"osteoporosis"
],
[
"osteoporosis",
"{u} (Disease) is treated by {v} (Compound)",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} may decrease the therapeutic efficacy of {v}",
"Tolfenamic acid"
],
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Calcium Phosphate"
],
[
"Calcium Phosphate",
"{u} may decrease the serum concentration of {v}",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} may decrease the serum concentration of {v}",
"Ibandronate"
],
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} may decrease the serum concentration of {v}",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Etidronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) treats {v} (Disease)",
"osteoporosis"
],
[
"osteoporosis",
"{u} (Disease) is treated by {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Etidronic acid"
]
]
] |
Calcium acetate may decrease the serum concentration of Ibandronate and Ibandronate (Compound) resembles Etidronic acid (Compound)
Calcium acetate may decrease the serum concentration of Clodronic acid and Clodronic acid (Compound) resembles Etidronic acid (Compound)
Calcium acetate (Compound) treats osteoporosis (Disease) and osteoporosis (Disease) is treated by Etidronic acid (Compound)
Calcium acetate (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Etidronic acid (Compound)
Calcium acetate may decrease the therapeutic efficacy of Tolfenamic acid and Tolfenamic acid may increase the severity of adverse effects when combined with Etidronic acid
Calcium acetate may increase the severity of adverse effects when combined with Calcium Phosphate and Calcium Phosphate may decrease the serum concentration of Etidronic acid
Calcium acetate may decrease the serum concentration of Ibandronate and Ibandronate (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid (Compound) resembles Etidronic acid (Compound)
Calcium acetate may decrease the serum concentration of Alendronic acid and Alendronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate (Compound) resembles Etidronic acid (Compound)
Calcium acetate (Compound) treats osteoporosis (Disease) and osteoporosis (Disease) is treated by Ibandronate (Compound) and Ibandronate (Compound) resembles Etidronic acid (Compound)
|
DB00712
|
DB00035
| 388 | 1,441 |
Flurbiprofen
|
Desmopressin
|
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
|
Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH. It has been employed clinically since 1972
|
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.
| 48 |
[
[
[
388,
71,
1441
]
],
[
[
388,
6,
3272
],
[
3272,
160,
1441
]
],
[
[
388,
21,
28965
],
[
28965,
175,
1441
]
],
[
[
388,
71,
833
],
[
833,
71,
1441
]
],
[
[
388,
182,
687
],
[
687,
71,
1441
]
],
[
[
388,
69,
861
],
[
861,
71,
1441
]
],
[
[
388,
180,
156
],
[
156,
71,
1441
]
],
[
[
388,
233,
768
],
[
768,
71,
1441
]
],
[
[
388,
155,
211
],
[
211,
71,
1441
]
],
[
[
388,
225,
770
],
[
770,
71,
1441
]
]
] |
[
[
[
"Flurbiprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolmetin"
],
[
"Tolmetin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} may increase the nephrotoxic activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desmopressin"
]
],
[
[
"Flurbiprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Floctafenine"
],
[
"Floctafenine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desmopressin"
]
]
] |
Flurbiprofen (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Desmopressin (Compound)
Flurbiprofen (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Desmopressin (Compound)
Flurbiprofen may increase the severity of adverse effects when combined with Tolmetin and Tolmetin may increase the severity of adverse effects when combined with Desmopressin
Flurbiprofen may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the severity of adverse effects when combined with Desmopressin
Flurbiprofen may decrease the metabolism of Fluvoxamine and Fluvoxamine may increase the severity of adverse effects when combined with Desmopressin
Flurbiprofen can increase the metabolism of Carbamazepine and Carbamazepine may increase the severity of adverse effects when combined with Desmopressin
Flurbiprofen may increase the nephrotoxic activities of Olsalazine and Olsalazine may increase the severity of adverse effects when combined with Desmopressin
Flurbiprofen (Compound) resembles Ketoprofen (Compound) and Ketoprofen may increase the severity of adverse effects when combined with Desmopressin
Flurbiprofen may increase the severity of adverse effects when combined with Floctafenine and Floctafenine may increase the severity of adverse effects when combined with Desmopressin
|
DB06697
|
DB01149
| 539 | 648 |
Artemether
|
Nefazodone
|
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
|
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
|
The metabolism of Nefazodone can be decreased when combined with Artemether.
| 46 |
[
[
[
539,
69,
648
]
],
[
[
539,
249,
1014
],
[
1014,
155,
648
]
],
[
[
539,
223,
370
],
[
370,
95,
648
]
],
[
[
539,
42,
1262
],
[
1262,
71,
648
]
],
[
[
539,
249,
940
],
[
940,
225,
648
]
],
[
[
539,
97,
932
],
[
932,
95,
648
]
],
[
[
539,
6,
8607
],
[
8607,
160,
648
]
],
[
[
539,
187,
173
],
[
173,
26,
648
]
],
[
[
539,
295,
150
],
[
150,
26,
648
]
],
[
[
539,
289,
164
],
[
164,
26,
648
]
]
] |
[
[
[
"Artemether",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} may increase the serum concentration of {v}",
"Fluphenazine"
],
[
"Fluphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} may decrease the metabolism of {v}",
"Domperidone"
],
[
"Domperidone",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} may increase the serum concentration of {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} may decrease the serum concentration of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} may reduce the serum concentration of the active metabolites of {v} and {u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Artemether",
"{u} can increase the metabolism of {v} and {u} may reduce the serum concentration of the active metabolites of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Nefazodone"
]
]
] |
Artemether may increase the serum concentration of Fluphenazine and Fluphenazine (Compound) resembles Nefazodone (Compound)
Artemether may decrease the metabolism of Domperidone and Domperidone may increase the serum concentration of Nefazodone
Artemether may increase the QTc prolonging activities of Hydroxyzine and Hydroxyzine may increase the severity of adverse effects when combined with Nefazodone
Artemether may increase the serum concentration of Trifluoperazine and Trifluoperazine may increase the severity of adverse effects when combined with Nefazodone
Artemether may decrease the serum concentration of Aripiprazole and Aripiprazole may increase the serum concentration of Nefazodone
Artemether (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Nefazodone (Compound)
Artemether may reduce the serum concentration of the active metabolites of Nevirapine and Nevirapine can increase the metabolism of Nefazodone
Artemether may reduce the serum concentration of the active metabolites of Fosphenytoin and Artemether may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Nefazodone
Artemether can increase the metabolism of Phenobarbital and Artemether may reduce the serum concentration of the active metabolites of Phenobarbital and Phenobarbital can increase the metabolism of Nefazodone
|
DB00952
|
DB00850
| 1,310 | 525 |
Naratriptan
|
Perphenazine
|
Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
|
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
|
The risk or severity of adverse effects can be increased when Naratriptan is combined with Perphenazine.
| 48 |
[
[
[
1310,
71,
525
]
],
[
[
1310,
71,
971
],
[
971,
225,
525
]
],
[
[
1310,
71,
5
],
[
5,
155,
525
]
],
[
[
1310,
71,
270
],
[
270,
71,
525
]
],
[
[
1310,
71,
1379
],
[
1379,
1,
525
]
],
[
[
1310,
71,
653
],
[
653,
95,
525
]
],
[
[
1310,
6,
10202
],
[
10202,
160,
525
]
],
[
[
1310,
21,
28387
],
[
28387,
175,
525
]
],
[
[
1310,
225,
543
],
[
543,
38,
525
]
],
[
[
1310,
71,
997
],
[
997,
57,
525
]
]
] |
[
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyamemazine"
],
[
"Cyamemazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Periciazine"
],
[
"Periciazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} (Compound) binds {v} (Gene)",
"HTR1A"
],
[
"HTR1A",
"{u} (Gene) is bound by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perphenazine"
]
],
[
[
"Naratriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Perphenazine"
]
]
] |
Naratriptan may increase the severity of adverse effects when combined with Zuclopenthixol and Zuclopenthixol may increase the severity of adverse effects when combined with Perphenazine
Naratriptan may increase the severity of adverse effects when combined with Cyamemazine and Cyamemazine (Compound) resembles Perphenazine (Compound)
Naratriptan may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Perphenazine
Naratriptan may increase the severity of adverse effects when combined with Periciazine and Periciazine (Compound) resembles Perphenazine (Compound)
Naratriptan may increase the severity of adverse effects when combined with Thioridazine and Thioridazine may increase the serum concentration of Perphenazine
Naratriptan (Compound) binds HTR1A (Gene) and HTR1A (Gene) is bound by Perphenazine (Compound)
Naratriptan (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Perphenazine (Compound)
Naratriptan may increase the severity of adverse effects when combined with Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Perphenazine
Naratriptan may increase the severity of adverse effects when combined with Lithium cation and Lithium cation may increase the neurotoxic activities of Perphenazine
|
DB01220
|
DB00321
| 218 | 262 |
Rifaximin
|
Amitriptyline
|
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.
|
Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
|
The serum concentration of Amitriptyline can be increased when it is combined with Rifaximin.
| 72 |
[
[
[
218,
95,
262
]
],
[
[
218,
26,
169
],
[
169,
28,
262
]
],
[
[
218,
95,
967
],
[
967,
71,
262
]
],
[
[
218,
6,
4590
],
[
4590,
160,
262
]
],
[
[
218,
21,
28440
],
[
28440,
175,
262
]
],
[
[
218,
26,
194
],
[
194,
26,
262
]
],
[
[
218,
97,
287
],
[
287,
38,
262
]
],
[
[
218,
97,
405
],
[
405,
192,
262
]
],
[
[
218,
95,
491
],
[
491,
38,
262
]
],
[
[
218,
95,
413
],
[
413,
42,
262
]
]
] |
[
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} can increase the metabolism of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} can increase the metabolism of {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} can increase the metabolism of {v}",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} may decrease the serum concentration of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} may decrease the serum concentration of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Amitriptyline"
]
],
[
[
"Rifaximin",
"{u} may increase the serum concentration of {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may increase the QTc prolonging activities of {v}",
"Amitriptyline"
]
]
] |
Rifaximin can increase the metabolism of Phenindione and Phenindione may increase the anticoagulant activities of Amitriptyline
Rifaximin may increase the serum concentration of Chlorprothixene and Chlorprothixene may increase the severity of adverse effects when combined with Amitriptyline
Rifaximin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Amitriptyline (Compound)
Rifaximin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Amitriptyline (Compound)
Rifaximin can increase the metabolism of Methylphenobarbital and Methylphenobarbital can increase the metabolism of Amitriptyline
Rifaximin may decrease the serum concentration of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Amitriptyline
Rifaximin may decrease the serum concentration of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Amitriptyline
Rifaximin may increase the serum concentration of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Amitriptyline
Rifaximin may increase the serum concentration of Pimozide and Pimozide may increase the QTc prolonging activities of Amitriptyline
|
DB00898
|
DB00207
| 587 | 645 |
Ethanol
|
Azithromycin
|
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
|
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small
|
The metabolism of Azithromycin can be decreased when combined with Ethanol.
| 46 |
[
[
[
587,
69,
645
]
],
[
[
587,
69,
143
],
[
143,
196,
645
]
],
[
[
587,
6,
12128
],
[
12128,
160,
645
]
],
[
[
587,
192,
142
],
[
142,
26,
645
]
],
[
[
587,
180,
147
],
[
147,
26,
645
]
],
[
[
587,
38,
156
],
[
156,
26,
645
]
],
[
[
587,
71,
878
],
[
878,
196,
645
]
],
[
[
587,
38,
931
],
[
931,
42,
645
]
],
[
[
587,
38,
992
],
[
992,
196,
645
]
],
[
[
587,
192,
543
],
[
543,
196,
645
]
]
] |
[
[
[
"Ethanol",
"{u} may decrease the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Flupentixol"
],
[
"Flupentixol",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
]
] |
Ethanol may decrease the metabolism of Erythromycin and Erythromycin may increase the QTc prolonging activities of Azithromycin
Ethanol (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Azithromycin (Compound)
Ethanol may increase the central nervous system depressant activities of Phenytoin and Phenytoin can increase the metabolism of Azithromycin
Ethanol can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Azithromycin
Ethanol may increase the central nervous system depressant activities of Carbamazepine and Carbamazepine can increase the metabolism of Azithromycin
Ethanol may increase the severity of adverse effects when combined with Paroxetine and Paroxetine may increase the QTc prolonging activities of Azithromycin
Ethanol may increase the central nervous system depressant activities of Flupentixol and Flupentixol may increase the QTc prolonging activities of Azithromycin
Ethanol may increase the central nervous system depressant activities of Olanzapine and Olanzapine may increase the QTc prolonging activities of Azithromycin
Ethanol may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the QTc prolonging activities of Azithromycin
|
DB00956
|
DB00237
| 1,083 | 994 |
Hydrocodone
|
Butabarbital
|
Hydrocodone is a synthetic opioid derivative of codeine. It is commonly used in combination with [acetaminophen] to control moderate to severe pain. Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations. Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain. The FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.
|
Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.
|
Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
| 15 |
[
[
[
1083,
38,
994
]
],
[
[
1083,
38,
197
],
[
197,
225,
994
]
],
[
[
1083,
21,
28463
],
[
28463,
175,
994
]
],
[
[
1083,
38,
674
],
[
674,
30,
994
]
],
[
[
1083,
38,
491
],
[
491,
38,
994
]
],
[
[
1083,
38,
1262
],
[
1262,
192,
994
]
],
[
[
1083,
54,
471
],
[
471,
208,
994
]
],
[
[
1083,
187,
878
],
[
878,
225,
994
]
],
[
[
1083,
38,
312
],
[
312,
71,
994
]
],
[
[
1083,
240,
324
],
[
324,
225,
994
]
]
] |
[
[
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Temazepam"
],
[
"Temazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butabarbital"
]
],
[
[
"Hydrocodone",
"{u} may increase the serotonergic activities of {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butabarbital"
]
]
] |
Hydrocodone may increase the central nervous system depressant activities of Amobarbital and Amobarbital may increase the severity of adverse effects when combined with Butabarbital
Hydrocodone (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Butabarbital (Compound)
Hydrocodone may increase the central nervous system depressant activities of Pregabalin and Pregabalin can increase the therapeutic efficacy of Butabarbital
Hydrocodone may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Butabarbital
Hydrocodone may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Butabarbital
Hydrocodone may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Butabarbital
Hydrocodone may reduce the serum concentration of the active metabolites of Paroxetine and Paroxetine may increase the severity of adverse effects when combined with Butabarbital
Hydrocodone may increase the central nervous system depressant activities of Temazepam and Temazepam may increase the severity of adverse effects when combined with Butabarbital
Hydrocodone may increase the serotonergic activities of Escitalopram and Escitalopram may increase the severity of adverse effects when combined with Butabarbital
|
DB00199
|
DB01190
| 143 | 484 |
Erythromycin
|
Clindamycin
|
Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of [Azithromycin], [Clarithromycin], [Spiramycin] and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria.[L5245,L7261] It is available for administration in various forms, including intravenous, topical, and eye drop preparations.
|
Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis. Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample.
|
The therapeutic efficacy of Clindamycin can be decreased when used in combination with Erythromycin.
| 69 |
[
[
[
143,
92,
484
]
],
[
[
143,
6,
4590
],
[
4590,
160,
484
]
],
[
[
143,
169,
24831
],
[
24831,
15,
484
]
],
[
[
143,
21,
29436
],
[
29436,
175,
484
]
],
[
[
143,
223,
156
],
[
156,
26,
484
]
],
[
[
143,
180,
147
],
[
147,
26,
484
]
],
[
[
143,
249,
530
],
[
530,
223,
484
]
],
[
[
143,
69,
1095
],
[
1095,
223,
484
]
],
[
[
143,
223,
482
],
[
482,
223,
484
]
],
[
[
143,
196,
575
],
[
575,
223,
484
]
]
] |
[
[
[
"Erythromycin",
"{u} may decrease the therapeutic efficacy of {v}",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Decreased Sebaceous Gland Activity"
],
[
"Decreased Sebaceous Gland Activity",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Redness"
],
[
"Redness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} may increase the serum concentration of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may decrease the metabolism of {v}",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may decrease the metabolism of {v}",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Clindamycin"
]
],
[
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may decrease the metabolism of {v}",
"Clindamycin"
]
]
] |
Erythromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Erythromycin (Compound) is included by Decreased Sebaceous Gland Activity (Pharmacologic Class) and Decreased Sebaceous Gland Activity (Pharmacologic Class) includes Clindamycin (Compound)
Erythromycin (Compound) causes Redness (Side Effect) and Redness (Side Effect) is caused by Clindamycin (Compound)
Erythromycin may decrease the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Clindamycin
Erythromycin can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Clindamycin
Erythromycin may increase the serum concentration of Dihydroergotamine and Dihydroergotamine may decrease the metabolism of Clindamycin
Erythromycin may decrease the metabolism of Cobicistat and Cobicistat may decrease the metabolism of Clindamycin
Erythromycin may decrease the metabolism of Verapamil and Verapamil may decrease the metabolism of Clindamycin
Erythromycin may increase the QTc prolonging activities of Sulfisoxazole and Sulfisoxazole may decrease the metabolism of Clindamycin
|
DB01628
|
DB00177
| 364 | 239 |
Etoricoxib
|
Valsartan
|
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
|
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [olmesartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via
|
The metabolism of Valsartan can be decreased when combined with Etoricoxib.
| 46 |
[
[
[
364,
69,
239
]
],
[
[
364,
225,
174
],
[
174,
155,
239
]
],
[
[
364,
69,
567
],
[
567,
155,
239
]
],
[
[
364,
225,
1054
],
[
1054,
225,
239
]
],
[
[
364,
6,
7128
],
[
7128,
160,
239
]
],
[
[
364,
21,
28921
],
[
28921,
175,
239
]
],
[
[
364,
180,
156
],
[
156,
26,
239
]
],
[
[
364,
95,
191
],
[
191,
26,
239
]
],
[
[
364,
69,
615
],
[
615,
32,
239
]
],
[
[
364,
69,
422
],
[
422,
223,
239
]
]
] |
[
[
[
"Etoricoxib",
"{u} may decrease the metabolism of {v}",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tasosartan"
],
[
"Tasosartan",
"{u} (Compound) resembles {v} (Compound)",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} may decrease the metabolism of {v}",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
],
[
"Olmesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} can increase the metabolism of {v}",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Valsartan"
]
],
[
[
"Etoricoxib",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may decrease the metabolism of {v}",
"Valsartan"
]
]
] |
Etoricoxib may increase the severity of adverse effects when combined with Tasosartan and Tasosartan (Compound) resembles Valsartan (Compound)
Etoricoxib may decrease the metabolism of Losartan and Losartan (Compound) resembles Valsartan (Compound)
Etoricoxib may increase the severity of adverse effects when combined with Olmesartan and Olmesartan may increase the severity of adverse effects when combined with Valsartan
Etoricoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Valsartan (Compound)
Etoricoxib (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Valsartan (Compound)
Etoricoxib can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Valsartan
Etoricoxib may increase the serum concentration of Aprepitant and Aprepitant can increase the metabolism of Valsartan
Etoricoxib may decrease the metabolism of Sildenafil and Sildenafil may increase the antihypertensive activities of Valsartan
Etoricoxib may decrease the metabolism of Midostaurin and Midostaurin may decrease the metabolism of Valsartan
|
DB01186
|
DB00675
| 369 | 568 |
Pergolide
|
Tamoxifen
|
Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
|
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
|
The risk or severity of adverse effects can be increased when Pergolide is combined with Tamoxifen.
| 48 |
[
[
[
369,
71,
568
]
],
[
[
369,
71,
1094
],
[
1094,
155,
568
]
],
[
[
369,
71,
574
],
[
574,
1,
568
]
],
[
[
369,
59,
195
],
[
195,
155,
568
]
],
[
[
369,
6,
4590
],
[
4590,
160,
568
]
],
[
[
369,
21,
28792
],
[
28792,
175,
568
]
],
[
[
369,
180,
156
],
[
156,
26,
568
]
],
[
[
369,
69,
613
],
[
613,
33,
568
]
],
[
[
369,
59,
438
],
[
438,
33,
568
]
],
[
[
369,
47,
1037
],
[
1037,
33,
568
]
]
] |
[
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomifene"
],
[
"Clomifene",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diethylstilbestrol"
],
[
"Diethylstilbestrol",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} may decrease the antihypertensive activities of {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} (Compound) causes {v} (Side Effect)",
"Arthralgia"
],
[
"Arthralgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} may decrease the antihypertensive activities of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
]
],
[
[
"Pergolide",
"{u} may increase the atrioventricular blocking activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
]
]
] |
Pergolide may increase the severity of adverse effects when combined with Clomifene and Clomifene (Compound) resembles Tamoxifen (Compound)
Pergolide may increase the severity of adverse effects when combined with Diethylstilbestrol and Diethylstilbestrol (Compound) resembles Tamoxifen (Compound)
Pergolide may decrease the antihypertensive activities of Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Tamoxifen (Compound)
Pergolide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tamoxifen (Compound)
Pergolide (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Tamoxifen (Compound)
Pergolide can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Tamoxifen
Pergolide may decrease the metabolism of Ticlopidine and Ticlopidine may reduce the serum concentration of the active metabolites of Tamoxifen
Pergolide may decrease the antihypertensive activities of Imipramine and Imipramine may reduce the serum concentration of the active metabolites of Tamoxifen
Pergolide may increase the atrioventricular blocking activities of Betaxolol and Betaxolol may reduce the serum concentration of the active metabolites of Tamoxifen
|
DB00908
|
DB01129
| 59 | 318 |
Quinidine
|
Rabeprazole
|
Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.[A38016,A250050] Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm. It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug. Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.
|
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
|
The metabolism of Rabeprazole can be decreased when combined with Quinidine.
| 46 |
[
[
[
59,
69,
318
]
],
[
[
59,
6,
12128
],
[
12128,
160,
318
]
],
[
[
59,
21,
28396
],
[
28396,
175,
318
]
],
[
[
59,
180,
173
],
[
173,
26,
318
]
],
[
[
59,
42,
150
],
[
150,
26,
318
]
],
[
[
59,
251,
147
],
[
147,
26,
318
]
],
[
[
59,
223,
228
],
[
228,
69,
318
]
],
[
[
59,
42,
638
],
[
638,
69,
318
]
],
[
[
59,
95,
198
],
[
198,
223,
318
]
],
[
[
59,
95,
452
],
[
452,
69,
318
]
]
] |
[
[
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} may increase the QTc prolonging activities of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Acetaminophen"
],
[
"Acetaminophen",
"{u} may decrease the metabolism of {v}",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} may increase the QTc prolonging activities of {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may decrease the metabolism of {v}",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Rabeprazole"
]
],
[
[
"Quinidine",
"{u} may increase the serum concentration of {v}",
"Ombitasvir"
],
[
"Ombitasvir",
"{u} may decrease the metabolism of {v}",
"Rabeprazole"
]
]
] |
Quinidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Rabeprazole (Compound)
Quinidine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Rabeprazole (Compound)
Quinidine can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Rabeprazole
Quinidine may increase the QTc prolonging activities of Fosphenytoin and Fosphenytoin can increase the metabolism of Rabeprazole
Quinidine may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Rabeprazole
Quinidine may decrease the metabolism of Acetaminophen and Acetaminophen may decrease the metabolism of Rabeprazole
Quinidine may increase the QTc prolonging activities of Olodaterol and Olodaterol may decrease the metabolism of Rabeprazole
Quinidine may increase the serum concentration of Cyclosporine and Cyclosporine may decrease the metabolism of Rabeprazole
Quinidine may increase the serum concentration of Ombitasvir and Ombitasvir may decrease the metabolism of Rabeprazole
|
DB01355
|
DB00697
| 298 | 730 |
Hexobarbital
|
Tizanidine
|
A barbiturate that is effective as a hypnotic and sedative.
|
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
|
The risk or severity of adverse effects can be increased when Hexobarbital is combined with Tizanidine.
| 48 |
[
[
[
298,
71,
730
]
],
[
[
298,
38,
702
],
[
702,
192,
730
]
],
[
[
298,
6,
12128
],
[
12128,
160,
730
]
],
[
[
298,
192,
1083
],
[
1083,
38,
730
]
],
[
[
298,
225,
971
],
[
971,
42,
730
]
],
[
[
298,
69,
429
],
[
429,
42,
730
]
],
[
[
298,
71,
956
],
[
956,
42,
730
]
],
[
[
298,
97,
1031
],
[
1031,
201,
730
]
],
[
[
298,
82,
248
],
[
248,
201,
730
]
],
[
[
298,
71,
911
],
[
911,
201,
730
]
]
] |
[
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the QTc prolonging activities of {v}",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} may decrease the serum concentration of {v}",
"Bevantolol"
],
[
"Bevantolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Tizanidine"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Tizanidine"
]
]
] |
Hexobarbital may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Tizanidine
Hexobarbital (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Hexobarbital may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Tizanidine
Hexobarbital may increase the severity of adverse effects when combined with Zuclopenthixol and Zuclopenthixol may increase the QTc prolonging activities of Tizanidine
Hexobarbital may decrease the metabolism of Lopinavir and Lopinavir may increase the QTc prolonging activities of Tizanidine
Hexobarbital may increase the severity of adverse effects when combined with Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Tizanidine
Hexobarbital may decrease the serum concentration of Bevantolol and Bevantolol may increase the atrioventricular blocking activities of Tizanidine
Hexobarbital may increase the hypotensive activities of Carvedilol and Carvedilol may increase the atrioventricular blocking activities of Tizanidine
Hexobarbital may increase the severity of adverse effects when combined with Oxprenolol and Oxprenolol may increase the atrioventricular blocking activities of Tizanidine
|
DB00204
|
DB00808
| 614 | 183 |
Dofetilide
|
Indapamide
|
Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
|
The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly,
|
Dofetilide may increase the QTc-prolonging activities of Indapamide.
| 19 |
[
[
[
614,
42,
183
]
],
[
[
614,
6,
4590
],
[
4590,
160,
183
]
],
[
[
614,
21,
28512
],
[
28512,
175,
183
]
],
[
[
614,
180,
177
],
[
177,
26,
183
]
],
[
[
614,
95,
173
],
[
173,
26,
183
]
],
[
[
614,
95,
615
],
[
615,
32,
183
]
],
[
[
614,
42,
154
],
[
154,
32,
183
]
],
[
[
614,
42,
1210
],
[
1210,
42,
183
]
],
[
[
614,
95,
539
],
[
539,
42,
183
]
],
[
[
614,
55,
394
],
[
394,
42,
183
]
]
] |
[
[
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may increase the antihypertensive activities of {v}",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} may increase the serum concentration of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the QTc prolonging activities of {v}",
"Indapamide"
]
],
[
[
"Dofetilide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Indapamide"
]
]
] |
Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indapamide (Compound)
Dofetilide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Indapamide (Compound)
Dofetilide can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Indapamide
Dofetilide may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Indapamide
Dofetilide may increase the serum concentration of Sildenafil and Sildenafil may increase the antihypertensive activities of Indapamide
Dofetilide may increase the QTc prolonging activities of Vardenafil and Vardenafil may increase the antihypertensive activities of Indapamide
Dofetilide may increase the QTc prolonging activities of Ofloxacin and Ofloxacin may increase the QTc prolonging activities of Indapamide
Dofetilide may increase the serum concentration of Artemether and Artemether may increase the QTc prolonging activities of Indapamide
Dofetilide may increase the severity of QTc prolonging effects when combined with Fluoxetine and Fluoxetine may increase the QTc prolonging activities of Indapamide
|
DB01590
|
DB01254
| 1,392 | 764 |
Everolimus
|
Dasatinib
|
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
|
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL
|
The serum concentration of Dasatinib can be increased when it is combined with Everolimus.
| 72 |
[
[
[
1392,
95,
764
]
],
[
[
1392,
6,
4590
],
[
4590,
160,
764
]
],
[
[
1392,
18,
2228
],
[
2228,
160,
764
]
],
[
[
1392,
7,
4220
],
[
4220,
160,
764
]
],
[
[
1392,
7,
8902
],
[
8902,
161,
764
]
],
[
[
1392,
18,
10735
],
[
10735,
161,
764
]
],
[
[
1392,
7,
4655
],
[
4655,
172,
764
]
],
[
[
1392,
18,
5234
],
[
5234,
172,
764
]
],
[
[
1392,
21,
28471
],
[
28471,
175,
764
]
],
[
[
1392,
95,
736
],
[
736,
28,
764
]
]
] |
[
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) downregulates {v} (Gene)",
"CSK"
],
[
"CSK",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"LYN"
],
[
"LYN",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"ZFP36"
],
[
"ZFP36",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) downregulates {v} (Gene)",
"DECR1"
],
[
"DECR1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"DNAJB1"
],
[
"DNAJB1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) downregulates {v} (Gene)",
"SUV39H1"
],
[
"SUV39H1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may increase the anticoagulant activities of {v}",
"Dasatinib"
]
]
] |
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Everolimus (Compound) downregulates CSK (Gene) and CSK (Gene) is bound by Dasatinib (Compound)
Everolimus (Compound) upregulates LYN (Gene) and LYN (Gene) is bound by Dasatinib (Compound)
Everolimus (Compound) upregulates ZFP36 (Gene) and ZFP36 (Gene) is upregulated by Dasatinib (Compound)
Everolimus (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is upregulated by Dasatinib (Compound)
Everolimus (Compound) upregulates DNAJB1 (Gene) and DNAJB1 (Gene) is downregulated by Dasatinib (Compound)
Everolimus (Compound) downregulates SUV39H1 (Gene) and SUV39H1 (Gene) is downregulated by Dasatinib (Compound)
Everolimus (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Dasatinib (Compound)
Everolimus may increase the serum concentration of Dipyridamole and Dipyridamole may increase the anticoagulant activities of Dasatinib
|
DB00834
|
DB01395
| 1,019 | 1,117 |
Mifepristone
|
Drospirenone
|
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
|
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thrombo
|
The therapeutic efficacy of Drospirenone can be decreased when used in combination with Mifepristone.
| 69 |
[
[
[
1019,
92,
1117
]
],
[
[
1019,
249,
386
],
[
386,
155,
1117
]
],
[
[
1019,
249,
462
],
[
462,
90,
1117
]
],
[
[
1019,
249,
458
],
[
458,
1,
1117
]
],
[
[
1019,
92,
108
],
[
108,
155,
1117
]
],
[
[
1019,
6,
4399
],
[
4399,
160,
1117
]
],
[
[
1019,
21,
28643
],
[
28643,
175,
1117
]
],
[
[
1019,
249,
342
],
[
342,
34,
1117
]
],
[
[
1019,
249,
1083
],
[
1083,
71,
1117
]
],
[
[
1019,
249,
304
],
[
304,
78,
1117
]
]
] |
[
[
[
"Mifepristone",
"{u} may decrease the therapeutic efficacy of {v}",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may increase the hyperkalemic activities of {v}",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Progesterone"
],
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} may decrease the therapeutic efficacy of {v}",
"Formestane"
],
[
"Formestane",
"{u} (Compound) resembles {v} (Compound)",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} (Compound) binds {v} (Gene)",
"PGR"
],
[
"PGR",
"{u} (Gene) is bound by {v} (Compound)",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may decrease the anticoagulant activities of {v}",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Drospirenone"
]
],
[
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Candesartan cilexetil"
],
[
"Candesartan cilexetil",
"{u} may increase the hypotensive effects when combined with {v}",
"Drospirenone"
]
]
] |
Mifepristone may increase the serum concentration of Norethisterone and Norethisterone (Compound) resembles Drospirenone (Compound)
Mifepristone may increase the serum concentration of Eplerenone and Eplerenone may increase the hyperkalemic activities of Drospirenone
Mifepristone may increase the serum concentration of Progesterone and Progesterone (Compound) resembles Drospirenone (Compound)
Mifepristone may decrease the therapeutic efficacy of Formestane and Formestane (Compound) resembles Drospirenone (Compound)
Mifepristone (Compound) binds PGR (Gene) and PGR (Gene) is bound by Drospirenone (Compound)
Mifepristone (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Drospirenone (Compound)
Mifepristone may increase the serum concentration of Acenocoumarol and Acenocoumarol may decrease the anticoagulant activities of Drospirenone
Mifepristone may increase the serum concentration of Hydrocodone and Hydrocodone may increase the severity of adverse effects when combined with Drospirenone
Mifepristone may increase the serum concentration of Candesartan cilexetil and Candesartan cilexetil may increase the hypotensive effects when combined with Drospirenone
|
DB00358
|
DB06702
| 285 | 35 |
Mefloquine
|
Fesoterodine
|
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
|
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
|
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mefloquine.
| 76 |
[
[
[
285,
99,
35
]
],
[
[
285,
196,
589
],
[
589,
1,
35
]
],
[
[
285,
6,
8339
],
[
8339,
160,
35
]
],
[
[
285,
21,
28450
],
[
28450,
175,
35
]
],
[
[
285,
92,
20
],
[
20,
24,
35
]
],
[
[
285,
92,
161
],
[
161,
26,
35
]
],
[
[
285,
180,
147
],
[
147,
26,
35
]
],
[
[
285,
69,
755
],
[
755,
223,
35
]
],
[
[
285,
196,
143
],
[
143,
223,
35
]
],
[
[
285,
92,
24
],
[
24,
225,
35
]
]
] |
[
[
[
"Mefloquine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} may increase the QTc prolonging activities of {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} may decrease the therapeutic efficacy of {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} may decrease the therapeutic efficacy of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} may increase the QTc prolonging activities of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Fesoterodine"
]
],
[
[
"Mefloquine",
"{u} may decrease the therapeutic efficacy of {v}",
"Methscopolamine bromide"
],
[
"Methscopolamine bromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fesoterodine"
]
]
] |
Mefloquine may increase the QTc prolonging activities of Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Compound)
Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fesoterodine (Compound)
Mefloquine (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Fesoterodine (Compound)
Mefloquine may decrease the therapeutic efficacy of Umeclidinium and Umeclidinium may increase the anticholinergic activities of Fesoterodine
Mefloquine may decrease the therapeutic efficacy of Primidone and Primidone can increase the metabolism of Fesoterodine
Mefloquine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Fesoterodine
Mefloquine may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Fesoterodine
Mefloquine may increase the QTc prolonging activities of Erythromycin and Erythromycin may decrease the metabolism of Fesoterodine
Mefloquine may decrease the therapeutic efficacy of Methscopolamine bromide and Methscopolamine bromide may increase the severity of adverse effects when combined with Fesoterodine
|
DB01149
|
DB04842
| 648 | 954 |
Nefazodone
|
Fluspirilene
|
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
|
A long-acting injectable antipsychotic agent used for chronic schizophrenia.
|
The risk or severity of adverse effects can be increased when Nefazodone is combined with Fluspirilene.
| 48 |
[
[
[
648,
71,
954
]
],
[
[
648,
225,
434
],
[
434,
225,
954
]
],
[
[
648,
223,
245
],
[
245,
71,
954
]
],
[
[
648,
6,
5586
],
[
5586,
160,
954
]
],
[
[
648,
18,
8775
],
[
8775,
172,
954
]
],
[
[
648,
225,
405
],
[
405,
192,
954
]
],
[
[
648,
249,
1261
],
[
1261,
192,
954
]
],
[
[
648,
225,
1266
],
[
1266,
38,
954
]
],
[
[
648,
223,
287
],
[
287,
38,
954
]
],
[
[
648,
223,
1257
],
[
1257,
192,
954
]
]
] |
[
[
[
"Nefazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"HTR2A"
],
[
"HTR2A",
"{u} (Gene) is bound by {v} (Compound)",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} (Compound) downregulates {v} (Gene)",
"CHMP4A"
],
[
"CHMP4A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} may increase the serum concentration of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluspirilene"
]
],
[
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluspirilene"
]
]
] |
Nefazodone may increase the severity of adverse effects when combined with Flunarizine and Flunarizine may increase the severity of adverse effects when combined with Fluspirilene
Nefazodone may decrease the metabolism of Haloperidol and Haloperidol may increase the severity of adverse effects when combined with Fluspirilene
Nefazodone (Compound) binds HTR2A (Gene) and HTR2A (Gene) is bound by Fluspirilene (Compound)
Nefazodone (Compound) downregulates CHMP4A (Gene) and CHMP4A (Gene) is downregulated by Fluspirilene (Compound)
Nefazodone may increase the severity of adverse effects when combined with Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Fluspirilene
Nefazodone may increase the serum concentration of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Fluspirilene
Nefazodone may increase the severity of adverse effects when combined with Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Fluspirilene
Nefazodone may decrease the metabolism of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Fluspirilene
Nefazodone may decrease the metabolism of Perampanel and Perampanel may increase the central nervous system depressant activities of Fluspirilene
|
DB01174
|
DB01424
| 164 | 374 |
Phenobarbital
|
Aminophenazone
|
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
|
Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests. The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942]
|
The metabolism of Aminophenazone can be increased when combined with Phenobarbital.
| 3 |
[
[
[
164,
26,
374
]
],
[
[
164,
116,
552
],
[
552,
155,
374
]
],
[
[
164,
6,
12846
],
[
12846,
160,
374
]
],
[
[
164,
26,
173
],
[
173,
26,
374
]
],
[
[
164,
38,
142
],
[
142,
26,
374
]
],
[
[
164,
270,
161
],
[
161,
26,
374
]
],
[
[
164,
97,
1085
],
[
1085,
223,
374
]
],
[
[
164,
26,
266
],
[
266,
223,
374
]
],
[
[
164,
71,
63
],
[
63,
223,
374
]
],
[
[
164,
69,
1417
],
[
1417,
223,
374
]
]
] |
[
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Methsuximide"
],
[
"Methsuximide",
"{u} (Compound) resembles {v} (Compound)",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} may decrease the serum concentration of {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may decrease the metabolism of {v}",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may decrease the metabolism of {v}",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may decrease the metabolism of {v}",
"Aminophenazone"
]
],
[
[
"Phenobarbital",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
],
[
"Topiroxostat",
"{u} may decrease the metabolism of {v}",
"Aminophenazone"
]
]
] |
Phenobarbital (Compound) resembles Methsuximide (Compound) and Phenobarbital may increase the severity of adverse effects when combined with Methsuximide and Methsuximide (Compound) resembles Aminophenazone (Compound)
Phenobarbital (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Aminophenazone (Compound)
Phenobarbital can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Aminophenazone
Phenobarbital may increase the central nervous system depressant activities of Phenytoin and Phenytoin can increase the metabolism of Aminophenazone
Phenobarbital (Compound) resembles Primidone (Compound) and Phenobarbital may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Aminophenazone
Phenobarbital may decrease the serum concentration of Olaparib and Olaparib may decrease the metabolism of Aminophenazone
Phenobarbital can increase the metabolism of Indinavir and Indinavir may decrease the metabolism of Aminophenazone
Phenobarbital may increase the severity of adverse effects when combined with Tranylcypromine and Tranylcypromine may decrease the metabolism of Aminophenazone
Phenobarbital may decrease the metabolism of Topiroxostat and Topiroxostat may decrease the metabolism of Aminophenazone
|
DB00768
|
DB09072
| 478 | 1,264 |
Olopatadine
|
Sodium oxybate
|
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of [doxepin], which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reactions. An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes. Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations. It is currently marketed
|
Sodium oxybate (Xyrem) is a central nervous system (CNS) depressant used to treat cataplexy or excessive daytime sleepiness associated with narcolepsy. It is a sodium salt of [gamma-Hydroxybutyric acid], an endogenous cerebral inhibitory neurotransmitter and a metabolite of the inhibitory neurotransmitter GABA. Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse. Sodium oxybate has been misused to stimulate body growth and to induce euphoria, disinhibition, and sexual arousal as a "party drug" or "club drug." For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries. An extended-release oral suspension formulation of sodium oxybate for narcolepsy, marketed under the brand name LUMRYZ, gained tentative FDA approval in July 2022 and was fully approved in May 2023. In some countries, sodium
|
Olopatadine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
| 15 |
[
[
[
478,
38,
1264
]
],
[
[
478,
225,
974
],
[
974,
38,
1264
]
],
[
[
478,
270,
438
],
[
438,
38,
1264
]
],
[
[
478,
192,
543
],
[
543,
38,
1264
]
],
[
[
478,
38,
1265
],
[
1265,
38,
1264
]
],
[
[
478,
71,
968
],
[
968,
38,
1264
]
],
[
[
478,
69,
861
],
[
861,
38,
1264
]
],
[
[
478,
249,
997
],
[
997,
38,
1264
]
],
[
[
478,
180,
142
],
[
142,
38,
1264
]
],
[
[
478,
155,
970
],
[
970,
38,
1264
]
]
] |
[
[
[
"Olopatadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"gamma-Hydroxybutyric acid"
],
[
"gamma-Hydroxybutyric acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} may increase the serum concentration of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
],
[
[
"Olopatadine",
"{u} (Compound) resembles {v} (Compound)",
"Thiothixene"
],
[
"Thiothixene",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
]
]
] |
Olopatadine may increase the severity of adverse effects when combined with gamma-Hydroxybutyric acid and gamma-Hydroxybutyric acid may increase the central nervous system depressant activities of Sodium oxybate
Olopatadine (Compound) resembles Imipramine (Compound) and Olopatadine may increase the severity of adverse effects when combined with Imipramine and Imipramine may increase the central nervous system depressant activities of Sodium oxybate
Olopatadine may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Sodium oxybate
Olopatadine may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Sodium oxybate
Olopatadine may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the central nervous system depressant activities of Sodium oxybate
Olopatadine may decrease the metabolism of Fluvoxamine and Fluvoxamine may increase the central nervous system depressant activities of Sodium oxybate
Olopatadine may increase the serum concentration of Lithium cation and Lithium cation may increase the central nervous system depressant activities of Sodium oxybate
Olopatadine can increase the metabolism of Phenytoin and Phenytoin may increase the central nervous system depressant activities of Sodium oxybate
Olopatadine (Compound) resembles Thiothixene (Compound) and Thiothixene may increase the central nervous system depressant activities of Sodium oxybate
|
DB00434
|
DB00835
| 30 | 165 |
Cyproheptadine
|
Brompheniramine
|
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
|
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
|
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brompheniramine.
| 48 |
[
[
[
30,
71,
165
]
],
[
[
30,
192,
72
],
[
72,
155,
165
]
],
[
[
30,
6,
8167
],
[
8167,
160,
165
]
],
[
[
30,
7,
14599
],
[
14599,
172,
165
]
],
[
[
30,
225,
164
],
[
164,
26,
165
]
],
[
[
30,
71,
150
],
[
150,
26,
165
]
],
[
[
30,
270,
156
],
[
156,
26,
165
]
],
[
[
30,
184,
674
],
[
674,
30,
165
]
],
[
[
30,
38,
1262
],
[
1262,
192,
165
]
],
[
[
30,
192,
1083
],
[
1083,
38,
165
]
]
] |
[
[
[
"Cyproheptadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) upregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brompheniramine"
]
],
[
[
"Cyproheptadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Brompheniramine"
]
]
] |
Cyproheptadine may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine (Compound) resembles Brompheniramine (Compound)
Cyproheptadine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Brompheniramine (Compound)
Cyproheptadine (Compound) upregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Brompheniramine (Compound)
Cyproheptadine may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital can increase the metabolism of Brompheniramine
Cyproheptadine may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin can increase the metabolism of Brompheniramine
Cyproheptadine (Compound) resembles Carbamazepine (Compound) and Cyproheptadine may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Brompheniramine
Cyproheptadine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Brompheniramine
Cyproheptadine may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Brompheniramine
Cyproheptadine may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Brompheniramine
|
DB00371
|
DB01018
| 464 | 643 |
Meprobamate
|
Guanfacine
|
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
|
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
|
The risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.
| 48 |
[
[
[
464,
71,
643
]
],
[
[
464,
6,
10999
],
[
10999,
160,
643
]
],
[
[
464,
21,
29305
],
[
29305,
175,
643
]
],
[
[
464,
246,
674
],
[
674,
30,
643
]
],
[
[
464,
38,
702
],
[
702,
32,
643
]
],
[
[
464,
38,
1257
],
[
1257,
192,
643
]
],
[
[
464,
192,
1266
],
[
1266,
38,
643
]
],
[
[
464,
71,
968
],
[
968,
206,
643
]
],
[
[
464,
54,
1365
],
[
1365,
208,
643
]
],
[
[
464,
71,
195
],
[
195,
213,
643
]
]
] |
[
[
[
"Meprobamate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} may decrease the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Guanfacine"
]
],
[
[
"Meprobamate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may decrease the antihypertensive activities of {v}",
"Guanfacine"
]
]
] |
Meprobamate (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Guanfacine (Compound)
Meprobamate (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Guanfacine (Compound)
Meprobamate may decrease the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Guanfacine
Meprobamate may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Guanfacine
Meprobamate may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Guanfacine
Meprobamate may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Guanfacine
Meprobamate may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Guanfacine
Meprobamate may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Guanfacine
Meprobamate may increase the severity of adverse effects when combined with Cyclobenzaprine and Cyclobenzaprine may decrease the antihypertensive activities of Guanfacine
|
DB09117
|
DB08918
| 1,266 | 193 |
Paraldehyde
|
Levomilnacipran
|
Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo effect.
|
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.
|
The risk or severity of adverse effects can be increased when Paraldehyde is combined with Levomilnacipran.
| 48 |
[
[
[
1266,
71,
193
]
],
[
[
1266,
71,
1021
],
[
1021,
71,
193
]
],
[
[
1266,
38,
465
],
[
465,
71,
193
]
],
[
[
1266,
38,
171
],
[
171,
26,
193
]
],
[
[
1266,
38,
587
],
[
587,
40,
193
]
],
[
[
1266,
38,
916
],
[
916,
59,
193
]
],
[
[
1266,
38,
245
],
[
245,
223,
193
]
],
[
[
1266,
38,
156
],
[
156,
69,
193
]
],
[
[
1266,
71,
394
],
[
394,
223,
193
]
],
[
[
1266,
38,
955
],
[
955,
225,
193
]
]
] |
[
[
[
"Paraldehyde",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the severity of adverse effects when combined with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Meperidine"
],
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} can increase the absorption and serum concentration of {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Etomidate"
],
[
"Etomidate",
"{u} may decrease the antihypertensive activities of {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may decrease the metabolism of {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may decrease the metabolism of {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may decrease the metabolism of {v}",
"Levomilnacipran"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
]
]
] |
Paraldehyde may increase the severity of adverse effects when combined with Milnacipran and Milnacipran may increase the severity of adverse effects when combined with Levomilnacipran
Paraldehyde may increase the central nervous system depressant activities of Meperidine and Meperidine may increase the severity of adverse effects when combined with Levomilnacipran
Paraldehyde may increase the central nervous system depressant activities of Pentobarbital and Pentobarbital can increase the metabolism of Levomilnacipran
Paraldehyde may increase the central nervous system depressant activities of Ethanol and Ethanol can increase the absorption and serum concentration of Levomilnacipran
Paraldehyde may increase the central nervous system depressant activities of Etomidate and Etomidate may decrease the antihypertensive activities of Levomilnacipran
Paraldehyde may increase the central nervous system depressant activities of Haloperidol and Haloperidol may decrease the metabolism of Levomilnacipran
Paraldehyde may increase the central nervous system depressant activities of Carbamazepine and Carbamazepine may decrease the metabolism of Levomilnacipran
Paraldehyde may increase the severity of adverse effects when combined with Fluoxetine and Fluoxetine may decrease the metabolism of Levomilnacipran
Paraldehyde may increase the central nervous system depressant activities of Quetiapine and Quetiapine may increase the severity of adverse effects when combined with Levomilnacipran
|
DB02187
|
DB00843
| 115 | 209 |
Equilin
|
Donepezil
|
An estrogenic steroid produced by horses. It has a total of four double bonds in the A- and B-ring. High concentration of equilin is found in the urine of pregnant mares.
|
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
|
The risk or severity of adverse effects can be increased when Equilin is combined with Donepezil.
| 48 |
[
[
[
115,
71,
209
]
],
[
[
115,
251,
173
],
[
173,
26,
209
]
],
[
[
115,
95,
564
],
[
564,
223,
209
]
],
[
[
115,
225,
588
],
[
588,
223,
209
]
],
[
[
115,
97,
1093
],
[
1093,
223,
209
]
],
[
[
115,
95,
124
],
[
124,
71,
209
]
],
[
[
115,
1,
79
],
[
79,
71,
209
]
],
[
[
115,
105,
1049
],
[
1049,
76,
209
]
],
[
[
115,
71,
264
],
[
264,
76,
209
]
],
[
[
115,
44,
25
],
[
25,
246,
209
]
]
] |
[
[
[
"Equilin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} may decrease the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} may increase the serum concentration of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may decrease the metabolism of {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may decrease the metabolism of {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} may decrease the serum concentration of {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may decrease the metabolism of {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} may increase the serum concentration of {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} (Compound) resembles {v} (Compound)",
"Estrone sulfate"
],
[
"Estrone sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} may increase the hypokalemic activities of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the bradycardic activities of {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Galantamine"
],
[
"Galantamine",
"{u} may increase the bradycardic activities of {v}",
"Donepezil"
]
],
[
[
"Equilin",
"{u} may increase the adverse neuromuscular activities of {v}",
"Atracurium besylate"
],
[
"Atracurium besylate",
"{u} may decrease the therapeutic efficacy of {v}",
"Donepezil"
]
]
] |
Equilin may decrease the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Donepezil
Equilin may increase the serum concentration of Atazanavir and Atazanavir may decrease the metabolism of Donepezil
Equilin may increase the severity of adverse effects when combined with Chloroquine and Chloroquine may decrease the metabolism of Donepezil
Equilin may decrease the serum concentration of Isoniazid and Isoniazid may decrease the metabolism of Donepezil
Equilin may increase the serum concentration of Estrone and Estrone may increase the severity of adverse effects when combined with Donepezil
Equilin (Compound) resembles Estrone sulfate (Compound) and Estrone sulfate may increase the severity of adverse effects when combined with Donepezil
Equilin may increase the hypokalemic activities of Bendroflumethiazide and Bendroflumethiazide may increase the bradycardic activities of Donepezil
Equilin may increase the severity of adverse effects when combined with Galantamine and Galantamine may increase the bradycardic activities of Donepezil
Equilin may increase the adverse neuromuscular activities of Atracurium besylate and Atracurium besylate may decrease the therapeutic efficacy of Donepezil
|
DB09009
|
DB01251
| 923 | 769 |
Articaine
|
Gliquidone
|
Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
|
Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
|
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Articaine.
| 69 |
[
[
[
923,
92,
769
]
],
[
[
923,
92,
326
],
[
326,
155,
769
]
],
[
[
923,
92,
473
],
[
473,
31,
769
]
],
[
[
923,
92,
693
],
[
693,
185,
769
]
],
[
[
923,
225,
911
],
[
911,
185,
769
]
],
[
[
923,
192,
587
],
[
587,
225,
769
]
],
[
[
923,
225,
494
],
[
494,
92,
769
]
],
[
[
923,
71,
957
],
[
957,
92,
769
]
],
[
[
923,
92,
326
],
[
326,
1,
792
],
[
792,
155,
769
]
],
[
[
923,
92,
473
],
[
473,
279,
326
],
[
326,
155,
769
]
]
] |
[
[
[
"Articaine",
"{u} may decrease the therapeutic efficacy of {v}",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may increase the hypoglycemic activities of {v}",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may decrease the therapeutic efficacy of {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the hypoglycemic activities of {v}",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Asenapine"
],
[
"Asenapine",
"{u} may decrease the therapeutic efficacy of {v}",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brexpiprazole"
],
[
"Brexpiprazole",
"{u} may decrease the therapeutic efficacy of {v}",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Glisoxepide"
],
[
"Glisoxepide",
"{u} (Compound) resembles {v} (Compound)",
"Gliquidone"
]
],
[
[
"Articaine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the hypoglycemic activities of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Gliquidone"
]
]
] |
Articaine may decrease the therapeutic efficacy of Glipizide and Glipizide (Compound) resembles Gliquidone (Compound)
Articaine may decrease the therapeutic efficacy of Glimepiride and Glimepiride may increase the hypoglycemic activities of Gliquidone
Articaine may decrease the therapeutic efficacy of Linagliptin and Linagliptin may increase the hypoglycemic activities of Gliquidone
Articaine may increase the severity of adverse effects when combined with Oxprenolol and Oxprenolol may increase the hypoglycemic activities of Gliquidone
Articaine may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the severity of adverse effects when combined with Gliquidone
Articaine may increase the severity of adverse effects when combined with Asenapine and Asenapine may decrease the therapeutic efficacy of Gliquidone
Articaine may increase the severity of adverse effects when combined with Brexpiprazole and Brexpiprazole may decrease the therapeutic efficacy of Gliquidone
Articaine may decrease the therapeutic efficacy of Glipizide and Glipizide (Compound) resembles Glisoxepide (Compound) and Glisoxepide (Compound) resembles Gliquidone (Compound)
Articaine may decrease the therapeutic efficacy of Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glimepiride may increase the hypoglycemic activities of Glipizide and Glipizide (Compound) resembles Gliquidone (Compound)
|
DB01036
|
DB00340
| 44 | 64 |
Tolterodine
|
Metixene
|
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
|
Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
|
The risk or severity of adverse effects can be increased when Tolterodine is combined with Metixene.
| 48 |
[
[
[
44,
71,
64
]
],
[
[
44,
196,
653
],
[
653,
1,
64
]
],
[
[
44,
196,
955
],
[
955,
155,
64
]
],
[
[
44,
24,
16
],
[
16,
178,
64
]
],
[
[
44,
6,
5535
],
[
5535,
160,
64
]
],
[
[
44,
178,
26
],
[
26,
24,
64
]
],
[
[
44,
71,
40
],
[
40,
71,
64
]
],
[
[
44,
71,
934
],
[
934,
225,
64
]
],
[
[
44,
225,
19
],
[
19,
71,
64
]
],
[
[
44,
196,
59
],
[
59,
71,
64
]
]
] |
[
[
[
"Tolterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} may increase the QTc prolonging activities of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} may increase the QTc prolonging activities of {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} may increase the anticholinergic activities of {v}",
"Mianserin"
],
[
"Mianserin",
"{u} may increase the anticholinergic activities of {v}",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} may increase the anticholinergic activities of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vecuronium"
],
[
"Vecuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Remifentanil"
],
[
"Remifentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Anisotropine methylbromide"
],
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Tolterodine",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
]
] |
Tolterodine may increase the QTc prolonging activities of Thioridazine and Thioridazine (Compound) resembles Metixene (Compound)
Tolterodine may increase the QTc prolonging activities of Quetiapine and Quetiapine (Compound) resembles Metixene (Compound)
Tolterodine may increase the anticholinergic activities of Mianserin and Mianserin may increase the anticholinergic activities of Metixene
Tolterodine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Metixene (Compound)
Tolterodine may increase the anticholinergic activities of Tiotropium and Tiotropium may increase the anticholinergic activities of Metixene
Tolterodine may increase the severity of adverse effects when combined with Vecuronium and Vecuronium may increase the severity of adverse effects when combined with Metixene
Tolterodine may increase the severity of adverse effects when combined with Remifentanil and Remifentanil may increase the severity of adverse effects when combined with Metixene
Tolterodine may increase the severity of adverse effects when combined with Anisotropine methylbromide and Anisotropine methylbromide may increase the severity of adverse effects when combined with Metixene
Tolterodine may increase the QTc prolonging activities of Quinidine and Quinidine may increase the severity of adverse effects when combined with Metixene
|
DB06820
|
DB00622
| 1,143 | 158 |
Sulconazole
|
Nicardipine
|
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial fungal infections.
|
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
|
The risk or severity of adverse effects can be increased when Sulconazole is combined with Nicardipine.
| 48 |
[
[
[
1143,
71,
158
]
],
[
[
1143,
71,
516
],
[
516,
225,
158
]
],
[
[
1143,
71,
435
],
[
435,
236,
158
]
],
[
[
1143,
71,
329
],
[
329,
155,
158
]
],
[
[
1143,
249,
147
],
[
147,
26,
158
]
],
[
[
1143,
249,
614
],
[
614,
42,
158
]
],
[
[
1143,
223,
254
],
[
254,
69,
158
]
],
[
[
1143,
71,
461
],
[
461,
69,
158
]
],
[
[
1143,
223,
198
],
[
198,
223,
158
]
],
[
[
1143,
249,
287
],
[
287,
69,
158
]
]
] |
[
[
[
"Sulconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nilvadipine"
],
[
"Nilvadipine",
"{u} may increase the hypotensive activities of {v}",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrendipine"
],
[
"Nitrendipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may increase the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may increase the serum concentration of {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may decrease the metabolism of {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may decrease the metabolism of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
]
],
[
[
"Sulconazole",
"{u} may increase the serum concentration of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
]
]
] |
Sulconazole may increase the severity of adverse effects when combined with Felodipine and Felodipine may increase the severity of adverse effects when combined with Nicardipine
Sulconazole may increase the severity of adverse effects when combined with Nilvadipine and Nilvadipine may increase the hypotensive activities of Nicardipine
Sulconazole may increase the severity of adverse effects when combined with Nitrendipine and Nitrendipine (Compound) resembles Nicardipine (Compound)
Sulconazole may increase the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Nicardipine
Sulconazole may increase the serum concentration of Dofetilide and Dofetilide may increase the QTc prolonging activities of Nicardipine
Sulconazole may decrease the metabolism of Buspirone and Buspirone may decrease the metabolism of Nicardipine
Sulconazole may increase the severity of adverse effects when combined with Diltiazem and Diltiazem may decrease the metabolism of Nicardipine
Sulconazole may decrease the metabolism of Cyclosporine and Cyclosporine may decrease the metabolism of Nicardipine
Sulconazole may increase the serum concentration of Zolpidem and Zolpidem may decrease the metabolism of Nicardipine
|
DB09075
|
DB01032
| 744 | 1,401 |
Edoxaban
|
Probenecid
|
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and
|
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
|
The serum concentration of Probenecid can be increased when it is combined with Edoxaban.
| 72 |
[
[
[
744,
95,
1401
]
],
[
[
744,
95,
569
],
[
569,
1,
1401
]
],
[
[
744,
95,
526
],
[
526,
65,
1401
]
],
[
[
744,
97,
162
],
[
162,
69,
1401
]
],
[
[
744,
28,
739
],
[
739,
92,
1401
]
],
[
[
744,
28,
804
],
[
804,
95,
1401
]
],
[
[
744,
88,
1351
],
[
1351,
95,
1401
]
],
[
[
744,
95,
379
],
[
379,
95,
1401
]
],
[
[
744,
97,
497
],
[
497,
95,
1401
]
],
[
[
744,
95,
569
],
[
569,
1,
1528
],
[
1528,
1,
1401
]
]
] |
[
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Chlorpropamide"
],
[
"Chlorpropamide",
"{u} (Compound) resembles {v} (Compound)",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may decrease the protein binding of {v}",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may decrease the serum concentration of {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may decrease the metabolism of {v}",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Aminosalicylic acid"
],
[
"Aminosalicylic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Nabumetone"
],
[
"Nabumetone",
"{u} may increase the serum concentration of {v}",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may increase bleeding risks when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase the serum concentration of {v}",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may decrease the serum concentration of {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may increase the serum concentration of {v}",
"Probenecid"
]
],
[
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Chlorpropamide"
],
[
"Chlorpropamide",
"{u} (Compound) resembles {v} (Compound)",
"Sulfacetamide"
],
[
"Sulfacetamide",
"{u} (Compound) resembles {v} (Compound)",
"Probenecid"
]
]
] |
Edoxaban may increase the serum concentration of Chlorpropamide and Chlorpropamide (Compound) resembles Probenecid (Compound)
Edoxaban may increase the serum concentration of Glyburide and Glyburide may decrease the protein binding of Probenecid
Edoxaban may decrease the serum concentration of Zidovudine and Zidovudine may decrease the metabolism of Probenecid
Edoxaban may increase the anticoagulant activities of Aminosalicylic acid and Aminosalicylic acid may decrease the therapeutic efficacy of Probenecid
Edoxaban may increase the anticoagulant activities of Nabumetone and Nabumetone may increase the serum concentration of Probenecid
Edoxaban may increase bleeding risks when combined with Acemetacin and Acemetacin may increase the serum concentration of Probenecid
Edoxaban may increase the serum concentration of Ranolazine and Ranolazine may increase the serum concentration of Probenecid
Edoxaban may decrease the serum concentration of Theophylline and Theophylline may increase the serum concentration of Probenecid
Edoxaban may increase the serum concentration of Chlorpropamide and Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Probenecid (Compound)
|
DB00363
|
DB01054
| 681 | 329 |
Clozapine
|
Nitrendipine
|
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although
|
Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
|
The risk or severity of adverse effects can be increased when Clozapine is combined with Nitrendipine.
| 48 |
[
[
[
681,
71,
329
]
],
[
[
681,
71,
435
],
[
435,
1,
329
]
],
[
[
681,
69,
158
],
[
158,
1,
329
]
],
[
[
681,
6,
8339
],
[
8339,
160,
329
]
],
[
[
681,
251,
164
],
[
164,
26,
329
]
],
[
[
681,
71,
197
],
[
197,
26,
329
]
],
[
[
681,
38,
702
],
[
702,
32,
329
]
],
[
[
681,
42,
154
],
[
154,
32,
329
]
],
[
[
681,
52,
968
],
[
968,
206,
329
]
],
[
[
681,
95,
828
],
[
828,
206,
329
]
]
] |
[
[
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nilvadipine"
],
[
"Nilvadipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} can increase the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} may increase the QTc prolonging activities of {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may increase the antihypertensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Clozapine",
"{u} may increase the serum concentration of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Nitrendipine"
]
]
] |
Clozapine may increase the severity of adverse effects when combined with Nilvadipine and Nilvadipine (Compound) resembles Nitrendipine (Compound)
Clozapine may decrease the metabolism of Nicardipine and Nicardipine (Compound) resembles Nitrendipine (Compound)
Clozapine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nitrendipine (Compound)
Clozapine may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Nitrendipine
Clozapine may increase the severity of adverse effects when combined with Amobarbital and Amobarbital can increase the metabolism of Nitrendipine
Clozapine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Nitrendipine
Clozapine may increase the QTc prolonging activities of Vardenafil and Vardenafil may increase the antihypertensive activities of Nitrendipine
Clozapine may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Nitrendipine
Clozapine may increase the serum concentration of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Nitrendipine
|
DB00682
|
DB00367
| 219 | 606 |
Warfarin
|
Levonorgestrel
|
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
|
Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of these devices are known as Jaydess, Kyleena, and Mirena. A subdermal implant of levonorgestrel that slowly releases the hormone over a long-term period is also available. In addition to the above uses, levonorgestrel is used as a component of long-term combination contraceptives.[A181991,L7760,L7778] Globally, levonorgestrel is the most commonly used emergency contraceptive. It was initially granted FDA approval in 1982 and was the first emergency contraceptive containing only progesterone, showing high levels of efficacy and a lack of estrogen
|
Warfarin may decrease the anticoagulant activities of Levonorgestrel.
| 11 |
[
[
[
219,
34,
606
]
],
[
[
219,
246,
386
],
[
386,
1,
606
]
],
[
[
219,
28,
806
],
[
806,
155,
606
]
],
[
[
219,
34,
1129
],
[
1129,
155,
606
]
],
[
[
219,
28,
811
],
[
811,
1,
606
]
],
[
[
219,
34,
622
],
[
622,
1,
606
]
],
[
[
219,
6,
4590
],
[
4590,
160,
606
]
],
[
[
219,
180,
171
],
[
171,
26,
606
]
],
[
[
219,
182,
384
],
[
384,
34,
606
]
],
[
[
219,
131,
498
],
[
498,
34,
606
]
]
] |
[
[
[
"Warfarin",
"{u} may decrease the anticoagulant activities of {v}",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} may decrease the therapeutic efficacy of {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Nandrolone decanoate"
],
[
"Nandrolone decanoate",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} may decrease the anticoagulant activities of {v}",
"Quinestrol"
],
[
"Quinestrol",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Testosterone propionate"
],
[
"Testosterone propionate",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} may decrease the anticoagulant activities of {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may decrease the anticoagulant activities of {v}",
"Levonorgestrel"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may decrease the anticoagulant activities of {v}",
"Levonorgestrel"
]
]
] |
Warfarin may decrease the therapeutic efficacy of Norethisterone and Norethisterone (Compound) resembles Levonorgestrel (Compound)
Warfarin may increase the anticoagulant activities of Nandrolone decanoate and Nandrolone decanoate (Compound) resembles Levonorgestrel (Compound)
Warfarin may decrease the anticoagulant activities of Quinestrol and Quinestrol (Compound) resembles Levonorgestrel (Compound)
Warfarin may increase the anticoagulant activities of Testosterone propionate and Testosterone propionate (Compound) resembles Levonorgestrel (Compound)
Warfarin may decrease the anticoagulant activities of Mestranol and Mestranol (Compound) resembles Levonorgestrel (Compound)
Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levonorgestrel (Compound)
Warfarin can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Levonorgestrel
Warfarin may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may decrease the anticoagulant activities of Levonorgestrel
Warfarin (Compound) resembles Dicoumarol (Compound) and Warfarin may increase the anticoagulant activities of Dicoumarol and Dicoumarol may decrease the anticoagulant activities of Levonorgestrel
|
DB04272
|
DB00946
| 773 | 384 |
Citric acid
|
Phenprocoumon
|
A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability. Citric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020. It is also used in combination with magnesium oxide to form magnesium citrate, an osmotic laxative.
|
Coumarin derivative that acts as a long-acting oral anticoagulant.
|
Citric acid may increase the anticoagulant activities of Phenprocoumon.
| 5 |
[
[
[
773,
28,
384
]
],
[
[
773,
28,
219
],
[
219,
182,
384
]
],
[
[
773,
28,
745
],
[
745,
1,
384
]
],
[
[
773,
182,
794
],
[
794,
28,
384
]
],
[
[
773,
34,
1129
],
[
1129,
188,
384
]
],
[
[
773,
246,
378
],
[
378,
188,
384
]
],
[
[
773,
28,
613
],
[
613,
223,
384
]
],
[
[
773,
225,
1444
],
[
1444,
71,
384
]
],
[
[
773,
71,
1231
],
[
1231,
225,
384
]
],
[
[
773,
88,
1351
],
[
1351,
242,
384
]
]
] |
[
[
[
"Citric acid",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may increase the anticoagulant activities of {v}",
"Fenoprofen"
],
[
"Fenoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may increase the anticoagulant activities of {v}",
"Protocatechualdehyde"
],
[
"Protocatechualdehyde",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may decrease the anticoagulant activities of {v}",
"Quinestrol"
],
[
"Quinestrol",
"{u} may decrease the anticoagulant activities of {v}",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may decrease the anticoagulant activities of {v}",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Limaprost"
],
[
"Limaprost",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenprocoumon"
]
],
[
[
"Citric acid",
"{u} may increase bleeding risks when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase bleeding risks when combined with {v}",
"Phenprocoumon"
]
]
] |
Citric acid may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Phenprocoumon
Citric acid may increase the anticoagulant activities of Fenoprofen and Fenoprofen (Compound) resembles Phenprocoumon (Compound)
Citric acid may increase the anticoagulant activities of Protocatechualdehyde and Protocatechualdehyde may increase the anticoagulant activities of Phenprocoumon
Citric acid may decrease the anticoagulant activities of Quinestrol and Quinestrol may decrease the anticoagulant activities of Phenprocoumon
Citric acid may decrease the therapeutic efficacy of Etonogestrel and Etonogestrel may decrease the anticoagulant activities of Phenprocoumon
Citric acid may increase the anticoagulant activities of Ticlopidine and Ticlopidine may decrease the metabolism of Phenprocoumon
Citric acid may increase the severity of adverse effects when combined with Limaprost and Limaprost may increase the severity of adverse effects when combined with Phenprocoumon
Citric acid may increase the severity of adverse effects when combined with Nintedanib and Nintedanib may increase the severity of adverse effects when combined with Phenprocoumon
Citric acid may increase bleeding risks when combined with Acemetacin and Acemetacin may increase bleeding risks when combined with Phenprocoumon
|
DB00628
|
DB13872
| 335 | 910 |
Clorazepic acid
|
Lormetazepam
|
Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety.[A957,L44788] Following administration, clorazepate is rapidly converted to nordiazepam (N-desmethyldiazepam), its active metabolite, before entering systemic circulation. Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal hyperpolarization.[A256683,T883] The concomitant use of clorazepate and opioids may result in profound sedation, respiratory depression, coma, and death. Also, the use of clorazepate exposes users to users to the risks of abuse, misuse, and addiction
|
Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia. It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.
|
The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Lormetazepam.
| 48 |
[
[
[
335,
71,
910
]
],
[
[
335,
192,
1266
],
[
1266,
38,
910
]
],
[
[
335,
38,
1264
],
[
1264,
192,
910
]
],
[
[
335,
54,
1046
],
[
1046,
208,
910
]
],
[
[
335,
225,
579
],
[
579,
71,
910
]
],
[
[
335,
71,
828
],
[
828,
225,
910
]
],
[
[
335,
71,
595
],
[
595,
71,
910
]
],
[
[
335,
69,
648
],
[
648,
225,
910
]
],
[
[
335,
155,
407
],
[
407,
71,
910
]
],
[
[
335,
69,
861
],
[
861,
71,
910
]
]
] |
[
[
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Codeine"
],
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perospirone"
],
[
"Perospirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} (Compound) resembles {v} (Compound)",
"Diazepam"
],
[
"Diazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
],
[
[
"Clorazepic acid",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lormetazepam"
]
]
] |
Clorazepic acid may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Lormetazepam
Clorazepic acid may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Lormetazepam
Clorazepic acid may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Lormetazepam
Clorazepic acid may increase the severity of adverse effects when combined with Codeine and Codeine may increase the severity of adverse effects when combined with Lormetazepam
Clorazepic acid may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the severity of adverse effects when combined with Lormetazepam
Clorazepic acid may increase the severity of adverse effects when combined with Perospirone and Perospirone may increase the severity of adverse effects when combined with Lormetazepam
Clorazepic acid may decrease the metabolism of Nefazodone and Nefazodone may increase the severity of adverse effects when combined with Lormetazepam
Clorazepic acid (Compound) resembles Diazepam (Compound) and Diazepam may increase the severity of adverse effects when combined with Lormetazepam
Clorazepic acid may decrease the metabolism of Fluvoxamine and Fluvoxamine may increase the severity of adverse effects when combined with Lormetazepam
|
DB00435
|
DB00698
| 1,366 | 1,507 |
Nitric Oxide
|
Nitrofurantoin
|
Nitric oxide or Nitrogen monoxide is a chemical compound with chemical formula NO. This gas is an important signaling molecule in the body of mammals including humans and is an extremely important intermediate in the chemical industry. It is also a toxic air pollutant produced by automobile engines and power plants. Nitric oxide (NO) should not be confused with nitrous oxide (N2O), a general anaesthetic, or with nitrogen dioxide (NO2) which is another poisonous air pollutant. The nitric oxide molecule is a free radical, which is relevant to understanding its high reactivity. It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.
|
Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections.[L6856,L6859,L6862] Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to [trimethoprim]/[sulfamethoxazole]. Nitrofurantoin was granted FDA approval on 6 February 1953.
|
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nitrofurantoin.
| 48 |
[
[
[
1366,
71,
1507
]
],
[
[
1366,
21,
28512
],
[
28512,
175,
1507
]
],
[
[
1366,
71,
917
],
[
917,
225,
1507
]
],
[
[
1366,
71,
462
],
[
462,
90,
1507
]
],
[
[
1366,
251,
814
],
[
814,
249,
1507
]
],
[
[
1366,
95,
495
],
[
495,
251,
1507
]
],
[
[
1366,
21,
28512
],
[
28512,
175,
273
],
[
273,
1,
1507
]
],
[
[
1366,
21,
28402
],
[
28402,
175,
462
],
[
462,
90,
1507
]
],
[
[
1366,
71,
917
],
[
917,
71,
273
],
[
273,
1,
1507
]
],
[
[
1366,
71,
462
],
[
462,
21,
28613
],
[
28613,
175,
1507
]
]
] |
[
[
[
"Nitric Oxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prilocaine"
],
[
"Prilocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may increase the hyperkalemic activities of {v}",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} may decrease the serum concentration of {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may increase the serum concentration of {v}",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may decrease the serum concentration of {v}",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dantrolene"
],
[
"Dantrolene",
"{u} (Compound) resembles {v} (Compound)",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Eplerenone"
],
[
"Eplerenone",
"{u} may increase the hyperkalemic activities of {v}",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prilocaine"
],
[
"Prilocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dantrolene"
],
[
"Dantrolene",
"{u} (Compound) resembles {v} (Compound)",
"Nitrofurantoin"
]
],
[
[
"Nitric Oxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nitrofurantoin"
]
]
] |
Nitric Oxide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Nitrofurantoin (Compound)
Nitric Oxide may increase the severity of adverse effects when combined with Prilocaine and Prilocaine may increase the severity of adverse effects when combined with Nitrofurantoin
Nitric Oxide may increase the severity of adverse effects when combined with Eplerenone and Eplerenone may increase the hyperkalemic activities of Nitrofurantoin
Nitric Oxide may decrease the serum concentration of Teriflunomide and Teriflunomide may increase the serum concentration of Nitrofurantoin
Nitric Oxide may increase the serum concentration of Vemurafenib and Vemurafenib may decrease the serum concentration of Nitrofurantoin
Nitric Oxide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Dantrolene (Compound) and Dantrolene (Compound) resembles Nitrofurantoin (Compound)
Nitric Oxide (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Eplerenone (Compound) and Eplerenone may increase the hyperkalemic activities of Nitrofurantoin
Nitric Oxide may increase the severity of adverse effects when combined with Prilocaine and Prilocaine may increase the severity of adverse effects when combined with Dantrolene and Dantrolene (Compound) resembles Nitrofurantoin (Compound)
Nitric Oxide may increase the severity of adverse effects when combined with Eplerenone and Eplerenone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Nitrofurantoin (Compound)
|
DB08922
|
DB00679
| 595 | 653 |
Perospirone
|
Thioridazine
|
Perospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors. It also displays affinity towards 5HT1A receptors as a partial agonist. Dainippon Sumitomo Pharma developed perospirone in Japan in 2001 for the treatment of acute schizophrenia and bipolar mania as well as chronic schizophrenia. It is commonly present as the hydrated hydrochloride salt form. Classified as a neuroleptic agent, perospirone is shown to be effective against positive, negative and general symptoms in patients with schizophrenia. It is also shown to be less associated with extrapyramidal symptoms as a side effect compared to.
|
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
|
The metabolism of Thioridazine can be decreased when combined with Perospirone.
| 46 |
[
[
[
595,
69,
653
]
],
[
[
595,
225,
288
],
[
288,
249,
653
]
],
[
[
595,
225,
270
],
[
270,
69,
653
]
],
[
[
595,
225,
973
],
[
973,
155,
653
]
],
[
[
595,
225,
940
],
[
940,
1,
653
]
],
[
[
595,
180,
150
],
[
150,
26,
653
]
],
[
[
595,
184,
674
],
[
674,
30,
653
]
],
[
[
595,
192,
1083
],
[
1083,
38,
653
]
],
[
[
595,
38,
1264
],
[
1264,
192,
653
]
],
[
[
595,
92,
1304
],
[
1304,
196,
653
]
]
] |
[
[
[
"Perospirone",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Promazine"
],
[
"Promazine",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Thioridazine"
]
],
[
[
"Perospirone",
"{u} may decrease the therapeutic efficacy of {v}",
"Apomorphine"
],
[
"Apomorphine",
"{u} may increase the QTc prolonging activities of {v}",
"Thioridazine"
]
]
] |
Perospirone may increase the severity of adverse effects when combined with Promazine and Promazine may increase the serum concentration of Thioridazine
Perospirone may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine may decrease the metabolism of Thioridazine
Perospirone may increase the severity of adverse effects when combined with Aceprometazine and Aceprometazine (Compound) resembles Thioridazine (Compound)
Perospirone may increase the severity of adverse effects when combined with Trifluoperazine and Trifluoperazine (Compound) resembles Thioridazine (Compound)
Perospirone can increase the metabolism of Fosphenytoin and Fosphenytoin can increase the metabolism of Thioridazine
Perospirone can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Thioridazine
Perospirone may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Thioridazine
Perospirone may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Thioridazine
Perospirone may decrease the therapeutic efficacy of Apomorphine and Apomorphine may increase the QTc prolonging activities of Thioridazine
|
DB00521
|
DB00800
| 1,035 | 1,058 |
Carteolol
|
Fenoldopam
|
A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
|
A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
|
Carteolol may increase the hypotensive activities of Fenoldopam.
| 59 |
[
[
[
1035,
82,
1058
]
],
[
[
1035,
21,
28437
],
[
28437,
175,
1058
]
],
[
[
1035,
186,
615
],
[
615,
32,
1058
]
],
[
[
1035,
52,
968
],
[
968,
206,
1058
]
],
[
[
1035,
225,
280
],
[
280,
225,
1058
]
],
[
[
1035,
71,
534
],
[
534,
225,
1058
]
],
[
[
1035,
225,
1353
],
[
1353,
71,
1058
]
],
[
[
1035,
52,
509
],
[
509,
225,
1058
]
],
[
[
1035,
69,
499
],
[
499,
71,
1058
]
],
[
[
1035,
201,
247
],
[
247,
71,
1058
]
]
] |
[
[
[
"Carteolol",
"{u} may increase the hypotensive activities of {v}",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} (Compound) causes {v} (Side Effect)",
"Bradycardia"
],
[
"Bradycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propofol"
],
[
"Propofol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isosorbide mononitrate"
],
[
"Isosorbide mononitrate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbetocin"
],
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Tamsulosin"
],
[
"Tamsulosin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} may decrease the metabolism of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fenoldopam"
]
],
[
[
"Carteolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fenoldopam"
]
]
] |
Carteolol (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Fenoldopam (Compound)
Carteolol may increase the antihypertensive activities of Sildenafil and Sildenafil may increase the antihypertensive activities of Fenoldopam
Carteolol may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Fenoldopam
Carteolol may increase the severity of adverse effects when combined with Propofol and Propofol may increase the severity of adverse effects when combined with Fenoldopam
Carteolol may increase the severity of adverse effects when combined with Isosorbide mononitrate and Isosorbide mononitrate may increase the severity of adverse effects when combined with Fenoldopam
Carteolol may increase the severity of adverse effects when combined with Carbetocin and Carbetocin may increase the severity of adverse effects when combined with Fenoldopam
Carteolol may increase the orthostatic hypotensive activities of Tamsulosin and Tamsulosin may increase the severity of adverse effects when combined with Fenoldopam
Carteolol may decrease the metabolism of Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Fenoldopam
Carteolol may increase the atrioventricular blocking activities of Bromocriptine and Bromocriptine may increase the severity of adverse effects when combined with Fenoldopam
|
DB00210
|
DB06730
| 785 | 1,089 |
Adapalene
|
Gestodene
|
Acne vulgaris is a multifactorial disorder of the pilosebaceous unit involving increased sebum production, inflammation, and hyperproliferation/hyperkeratinization of the follicular infundibulum. It is also associated with _Cutibacterium acnes_ (also known as _Propionibacterium acnes_). Adapalene is a third-generation topical retinoid used for the treatment of acne vulgaris. Adapalene has similar efficacy but a superior safety profile compared to tretinoin. [Tazarotene] is more efficacious than adapalene but is designated as pregnancy category X and hence is contraindicated in pregnant women. Adapalene can also be combined with benzoyl peroxide (BPO), which possesses bactericidal properties, and either adapalene alone, or adapalene BPO combination products, are commonly used to treat mild-to-severe acne. Differin
|
Gestodene is a progestogen hormonal contraceptive. Products containing gestoden include Meliane, which contains 20 mcg of ethinylestradiol and 75 mcg of gestodene; and Gynera, which contains 30 mcg of ethinylestradiol and 75 mcg of gestodene.
|
The therapeutic efficacy of Gestodene can be decreased when used in combination with Adapalene.
| 69 |
[
[
[
785,
92,
1089
]
],
[
[
785,
92,
1100
],
[
1100,
1,
1089
]
],
[
[
785,
92,
1104
],
[
1104,
155,
1089
]
],
[
[
785,
182,
169
],
[
169,
34,
1089
]
],
[
[
785,
182,
760
],
[
760,
246,
1089
]
],
[
[
785,
92,
1100
],
[
1100,
155,
1087
],
[
1087,
1,
1089
]
],
[
[
785,
182,
169
],
[
169,
34,
1100
],
[
1100,
1,
1089
]
],
[
[
785,
182,
384
],
[
384,
34,
1104
],
[
1104,
155,
1089
]
],
[
[
785,
182,
760
],
[
760,
246,
386
],
[
386,
1,
1089
]
],
[
[
785,
92,
622
],
[
622,
1,
1087
],
[
1087,
1,
1089
]
]
] |
[
[
[
"Adapalene",
"{u} may decrease the therapeutic efficacy of {v}",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may decrease the therapeutic efficacy of {v}",
"Norelgestromin"
],
[
"Norelgestromin",
"{u} (Compound) resembles {v} (Compound)",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may decrease the therapeutic efficacy of {v}",
"Norgestimate"
],
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may decrease the anticoagulant activities of {v}",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may increase the anticoagulant activities of {v}",
"Pentaerythritol tetranitrate"
],
[
"Pentaerythritol tetranitrate",
"{u} may decrease the therapeutic efficacy of {v}",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may decrease the therapeutic efficacy of {v}",
"Norelgestromin"
],
[
"Norelgestromin",
"{u} (Compound) resembles {v} (Compound)",
"Desogestrel"
],
[
"Desogestrel",
"{u} (Compound) resembles {v} (Compound)",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may decrease the anticoagulant activities of {v}",
"Norelgestromin"
],
[
"Norelgestromin",
"{u} (Compound) resembles {v} (Compound)",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may decrease the anticoagulant activities of {v}",
"Norgestimate"
],
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may increase the anticoagulant activities of {v}",
"Pentaerythritol tetranitrate"
],
[
"Pentaerythritol tetranitrate",
"{u} may decrease the therapeutic efficacy of {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Gestodene"
]
],
[
[
"Adapalene",
"{u} may decrease the therapeutic efficacy of {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Desogestrel"
],
[
"Desogestrel",
"{u} (Compound) resembles {v} (Compound)",
"Gestodene"
]
]
] |
Adapalene may decrease the therapeutic efficacy of Norelgestromin and Norelgestromin (Compound) resembles Gestodene (Compound)
Adapalene may decrease the therapeutic efficacy of Norgestimate and Norgestimate (Compound) resembles Gestodene (Compound)
Adapalene may increase the anticoagulant activities of Phenindione and Phenindione may decrease the anticoagulant activities of Gestodene
Adapalene may increase the anticoagulant activities of Pentaerythritol tetranitrate and Pentaerythritol tetranitrate may decrease the therapeutic efficacy of Gestodene
Adapalene may decrease the therapeutic efficacy of Norelgestromin and Norelgestromin (Compound) resembles Desogestrel (Compound) and Desogestrel (Compound) resembles Gestodene (Compound)
Adapalene may increase the anticoagulant activities of Phenindione and Phenindione may decrease the anticoagulant activities of Norelgestromin and Norelgestromin (Compound) resembles Gestodene (Compound)
Adapalene may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may decrease the anticoagulant activities of Norgestimate and Norgestimate (Compound) resembles Gestodene (Compound)
Adapalene may increase the anticoagulant activities of Pentaerythritol tetranitrate and Pentaerythritol tetranitrate may decrease the therapeutic efficacy of Norethisterone and Norethisterone (Compound) resembles Gestodene (Compound)
Adapalene may decrease the therapeutic efficacy of Mestranol and Mestranol (Compound) resembles Desogestrel (Compound) and Desogestrel (Compound) resembles Gestodene (Compound)
|
DB01624
|
DB01355
| 971 | 298 |
Zuclopenthixol
|
Hexobarbital
|
Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A)
|
A barbiturate that is effective as a hypnotic and sedative.
|
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Hexobarbital.
| 48 |
[
[
[
971,
71,
298
]
],
[
[
971,
71,
194
],
[
194,
155,
298
]
],
[
[
971,
251,
173
],
[
173,
26,
298
]
],
[
[
971,
42,
221
],
[
221,
180,
298
]
],
[
[
971,
225,
195
],
[
195,
180,
298
]
],
[
[
971,
95,
198
],
[
198,
180,
298
]
],
[
[
971,
38,
405
],
[
405,
192,
298
]
],
[
[
971,
192,
587
],
[
587,
38,
298
]
],
[
[
971,
1,
1262
],
[
1262,
192,
298
]
],
[
[
971,
225,
465
],
[
465,
38,
298
]
]
] |
[
[
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} may decrease the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the QTc prolonging activities of {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} can increase the metabolism of {v}",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} can increase the metabolism of {v}",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} can increase the metabolism of {v}",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hexobarbital"
]
],
[
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hexobarbital"
]
]
] |
Zuclopenthixol may increase the severity of adverse effects when combined with Methylphenobarbital and Methylphenobarbital (Compound) resembles Hexobarbital (Compound)
Zuclopenthixol may decrease the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Hexobarbital
Zuclopenthixol may increase the QTc prolonging activities of Nortriptyline and Nortriptyline can increase the metabolism of Hexobarbital
Zuclopenthixol may increase the severity of adverse effects when combined with Cyclobenzaprine and Cyclobenzaprine can increase the metabolism of Hexobarbital
Zuclopenthixol may increase the serum concentration of Cyclosporine and Cyclosporine can increase the metabolism of Hexobarbital
Zuclopenthixol may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Hexobarbital
Zuclopenthixol may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Hexobarbital
Zuclopenthixol (Compound) resembles Hydroxyzine (Compound) and Hydroxyzine may increase the central nervous system depressant activities of Hexobarbital
Zuclopenthixol may increase the severity of adverse effects when combined with Meperidine and Meperidine may increase the central nervous system depressant activities of Hexobarbital
|
DB01246
|
DB00497
| 1,448 | 163 |
Alimemazine
|
Oxycodone
|
A phenothiazine derivative that is used as an antipruritic.
|
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.
|
Alimemazine may increase the hypotensive activities of Oxycodone.
| 59 |
[
[
[
1448,
82,
163
]
],
[
[
1448,
82,
921
],
[
921,
225,
163
]
],
[
[
1448,
6,
4590
],
[
4590,
160,
163
]
],
[
[
1448,
21,
28598
],
[
28598,
175,
163
]
],
[
[
1448,
1,
156
],
[
156,
26,
163
]
],
[
[
1448,
1,
72
],
[
72,
38,
163
]
],
[
[
1448,
95,
640
],
[
640,
223,
163
]
],
[
[
1448,
82,
576
],
[
576,
223,
163
]
],
[
[
1448,
155,
392
],
[
392,
223,
163
]
],
[
[
1448,
116,
499
],
[
499,
223,
163
]
]
] |
[
[
[
"Alimemazine",
"{u} may increase the hypotensive activities of {v}",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} may increase the hypotensive activities of {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} (Compound) causes {v} (Side Effect)",
"Pulmonary function test decreased"
],
[
"Pulmonary function test decreased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} may increase the serum concentration of {v}",
"Quinine"
],
[
"Quinine",
"{u} may decrease the metabolism of {v}",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} may increase the hypotensive activities of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may decrease the metabolism of {v}",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may decrease the metabolism of {v}",
"Oxycodone"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may decrease the metabolism of {v}",
"Oxycodone"
]
]
] |
Alimemazine may increase the hypotensive activities of Nalbuphine and Nalbuphine may increase the severity of adverse effects when combined with Oxycodone
Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Oxycodone (Compound)
Alimemazine (Compound) causes Pulmonary function test decreased (Side Effect) and Pulmonary function test decreased (Side Effect) is caused by Oxycodone (Compound)
Alimemazine (Compound) resembles Carbamazepine (Compound) and Carbamazepine can increase the metabolism of Oxycodone
Alimemazine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may increase the central nervous system depressant activities of Oxycodone
Alimemazine may increase the serum concentration of Quinine and Quinine may decrease the metabolism of Oxycodone
Alimemazine may increase the hypotensive activities of Metoprolol and Metoprolol may decrease the metabolism of Oxycodone
Alimemazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may decrease the metabolism of Oxycodone
Alimemazine (Compound) resembles Clomipramine (Compound) and Alimemazine may increase the severity of adverse effects when combined with Clomipramine and Clomipramine may decrease the metabolism of Oxycodone
|
DB00323
|
DB04946
| 975 | 196 |
Tolcapone
|
Iloperidone
|
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
|
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
|
The risk or severity of adverse effects can be increased when Tolcapone is combined with Iloperidone.
| 48 |
[
[
[
975,
71,
196
]
],
[
[
975,
82,
453
],
[
453,
1,
196
]
],
[
[
975,
21,
28562
],
[
28562,
175,
196
]
],
[
[
975,
71,
161
],
[
161,
26,
196
]
],
[
[
975,
225,
171
],
[
171,
26,
196
]
],
[
[
975,
184,
674
],
[
674,
30,
196
]
],
[
[
975,
192,
679
],
[
679,
38,
196
]
],
[
[
975,
38,
1262
],
[
1262,
192,
196
]
],
[
[
975,
71,
158
],
[
158,
196,
196
]
],
[
[
975,
225,
914
],
[
914,
196,
196
]
]
] |
[
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} may increase the hypotensive activities of {v}",
"Risperidone"
],
[
"Risperidone",
"{u} (Compound) resembles {v} (Compound)",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may increase the QTc prolonging activities of {v}",
"Iloperidone"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
],
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Iloperidone"
]
]
] |
Tolcapone may increase the hypotensive activities of Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Tolcapone (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Iloperidone (Compound)
Tolcapone may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Iloperidone
Tolcapone may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Iloperidone
Tolcapone can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Iloperidone
Tolcapone may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Iloperidone
Tolcapone may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Iloperidone
Tolcapone may increase the severity of adverse effects when combined with Nicardipine and Nicardipine may increase the QTc prolonging activities of Iloperidone
Tolcapone may increase the severity of adverse effects when combined with Desflurane and Desflurane may increase the QTc prolonging activities of Iloperidone
|
DB00230
|
DB01018
| 674 | 643 |
Pregabalin
|
Guanfacine
|
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190,L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.
|
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
|
The therapeutic efficacy of Guanfacine can be increased when used in combination with Pregabalin.
| 7 |
[
[
[
674,
30,
643
]
],
[
[
674,
92,
1591
],
[
1591,
1,
643
]
],
[
[
674,
21,
28965
],
[
28965,
175,
643
]
],
[
[
674,
38,
702
],
[
702,
32,
643
]
],
[
[
674,
38,
1265
],
[
1265,
192,
643
]
],
[
[
674,
192,
1083
],
[
1083,
38,
643
]
],
[
[
674,
236,
248
],
[
248,
201,
643
]
],
[
[
674,
30,
911
],
[
911,
201,
643
]
],
[
[
674,
30,
968
],
[
968,
206,
643
]
],
[
[
674,
54,
1046
],
[
1046,
208,
643
]
]
] |
[
[
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} may decrease the therapeutic efficacy of {v}",
"Phenacemide"
],
[
"Phenacemide",
"{u} (Compound) resembles {v} (Compound)",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} may increase the hypotensive activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Guanfacine"
]
],
[
[
"Pregabalin",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Guanfacine"
]
]
] |
Pregabalin may decrease the therapeutic efficacy of Phenacemide and Phenacemide (Compound) resembles Guanfacine (Compound)
Pregabalin (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Guanfacine (Compound)
Pregabalin may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Guanfacine
Pregabalin may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Guanfacine
Pregabalin may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Guanfacine
Pregabalin may increase the hypotensive activities of Carvedilol and Carvedilol may increase the atrioventricular blocking activities of Guanfacine
Pregabalin can increase the therapeutic efficacy of Oxprenolol and Oxprenolol may increase the atrioventricular blocking activities of Guanfacine
Pregabalin can increase the therapeutic efficacy of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Guanfacine
Pregabalin may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Guanfacine
|
DB00571
|
DB12332
| 504 | 381 |
Propranolol
|
Rucaparib
|
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.
|
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]
|
The metabolism of Rucaparib can be decreased when combined with Propranolol.
| 46 |
[
[
[
504,
69,
381
]
],
[
[
504,
180,
177
],
[
177,
26,
381
]
],
[
[
504,
82,
435
],
[
435,
69,
381
]
],
[
[
504,
225,
679
],
[
679,
69,
381
]
],
[
[
504,
230,
651
],
[
651,
69,
381
]
],
[
[
504,
69,
55
],
[
55,
69,
381
]
],
[
[
504,
69,
648
],
[
648,
223,
381
]
],
[
[
504,
116,
1022
],
[
1022,
69,
381
]
],
[
[
504,
52,
968
],
[
968,
69,
381
]
],
[
[
504,
71,
534
],
[
534,
69,
381
]
]
] |
[
[
[
"Propranolol",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} may increase the hypotensive activities of {v}",
"Nilvadipine"
],
[
"Nilvadipine",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} may increase the bradycardic activities of {v}",
"Malathion"
],
[
"Malathion",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} may decrease the metabolism of {v}",
"Moclobemide"
],
[
"Moclobemide",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
],
[
[
"Propranolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isosorbide mononitrate"
],
[
"Isosorbide mononitrate",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
]
]
] |
Propranolol can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Rucaparib
Propranolol may increase the hypotensive activities of Nilvadipine and Nilvadipine may decrease the metabolism of Rucaparib
Propranolol may increase the severity of adverse effects when combined with Thalidomide and Thalidomide may decrease the metabolism of Rucaparib
Propranolol may increase the bradycardic activities of Malathion and Malathion may decrease the metabolism of Rucaparib
Propranolol may decrease the metabolism of Moclobemide and Moclobemide may decrease the metabolism of Rucaparib
Propranolol may decrease the metabolism of Nefazodone and Nefazodone may decrease the metabolism of Rucaparib
Propranolol (Compound) resembles Pindolol (Compound) and Propranolol may increase the severity of adverse effects when combined with Pindolol and Pindolol may decrease the metabolism of Rucaparib
Propranolol may increase the orthostatic hypotensive activities of Levodopa and Levodopa may decrease the metabolism of Rucaparib
Propranolol may increase the severity of adverse effects when combined with Isosorbide mononitrate and Isosorbide mononitrate may decrease the metabolism of Rucaparib
|
DB06605
|
DB01072
| 632 | 564 |
Apixaban
|
Atazanavir
|
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
|
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
|
The serum concentration of Atazanavir can be increased when it is combined with Apixaban.
| 72 |
[
[
[
632,
95,
564
]
],
[
[
632,
95,
429
],
[
429,
1,
564
]
],
[
[
632,
6,
8339
],
[
8339,
160,
564
]
],
[
[
632,
21,
29775
],
[
29775,
175,
564
]
],
[
[
632,
251,
150
],
[
150,
26,
564
]
],
[
[
632,
180,
156
],
[
156,
26,
564
]
],
[
[
632,
225,
795
],
[
795,
187,
564
]
],
[
[
632,
225,
784
],
[
784,
42,
564
]
],
[
[
632,
69,
567
],
[
567,
69,
564
]
],
[
[
632,
246,
265
],
[
265,
69,
564
]
]
] |
[
[
[
"Apixaban",
"{u} may increase the serum concentration of {v}",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} may increase the serum concentration of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} (Compound) causes {v} (Side Effect)",
"Alanine aminotransferase increased"
],
[
"Alanine aminotransferase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} may increase the severity of adverse effects when combined with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may increase the QTc prolonging activities of {v}",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} may decrease the metabolism of {v}",
"Losartan"
],
[
"Losartan",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Apixaban",
"{u} may decrease the therapeutic efficacy of {v}",
"Allylestrenol"
],
[
"Allylestrenol",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
]
]
] |
Apixaban may increase the serum concentration of Lopinavir and Lopinavir (Compound) resembles Atazanavir (Compound)
Apixaban (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Apixaban (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Atazanavir (Compound)
Apixaban may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Atazanavir
Apixaban can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Atazanavir
Apixaban may increase the severity of adverse effects when combined with Ticagrelor and Ticagrelor may reduce the serum concentration of the active metabolites of Atazanavir
Apixaban may increase the severity of adverse effects when combined with Anagrelide and Anagrelide may increase the QTc prolonging activities of Atazanavir
Apixaban may decrease the metabolism of Losartan and Losartan may decrease the metabolism of Atazanavir
Apixaban may decrease the therapeutic efficacy of Allylestrenol and Allylestrenol may decrease the metabolism of Atazanavir
|
DB01186
|
DB00255
| 369 | 574 |
Pergolide
|
Diethylstilbestrol
|
Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
|
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
|
The risk or severity of adverse effects can be increased when Pergolide is combined with Diethylstilbestrol.
| 48 |
[
[
[
369,
71,
574
]
],
[
[
369,
71,
568
],
[
568,
155,
574
]
],
[
[
369,
6,
4590
],
[
4590,
160,
574
]
],
[
[
369,
71,
243
],
[
243,
37,
574
]
],
[
[
369,
71,
654
],
[
654,
50,
574
]
],
[
[
369,
225,
1456
],
[
1456,
71,
574
]
],
[
[
369,
270,
308
],
[
308,
71,
574
]
],
[
[
369,
69,
530
],
[
530,
71,
574
]
],
[
[
369,
71,
292
],
[
292,
71,
574
]
],
[
[
369,
41,
376
],
[
376,
71,
574
]
]
] |
[
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound)",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tipranavir"
],
[
"Tipranavir",
"{u} may increase the dermatologic adverse activities of {v}",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methysergide"
],
[
"Methysergide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Lisuride"
],
[
"Lisuride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diethylstilbestrol"
]
],
[
[
"Pergolide",
"{u} may increase the vasoconstricting activities of {v}",
"Ergometrine"
],
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diethylstilbestrol"
]
]
] |
Pergolide may increase the severity of adverse effects when combined with Tamoxifen and Tamoxifen (Compound) resembles Diethylstilbestrol (Compound)
Pergolide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diethylstilbestrol (Compound)
Pergolide may increase the severity of adverse effects when combined with Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Diethylstilbestrol
Pergolide may increase the severity of adverse effects when combined with Tipranavir and Tipranavir may increase the dermatologic adverse activities of Diethylstilbestrol
Pergolide may increase the severity of adverse effects when combined with Methysergide and Methysergide may increase the severity of adverse effects when combined with Diethylstilbestrol
Pergolide (Compound) resembles Lisuride (Compound) and Pergolide may increase the severity of adverse effects when combined with Lisuride and Lisuride may increase the severity of adverse effects when combined with Diethylstilbestrol
Pergolide may decrease the metabolism of Dihydroergotamine and Dihydroergotamine may increase the severity of adverse effects when combined with Diethylstilbestrol
Pergolide may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may increase the severity of adverse effects when combined with Diethylstilbestrol
Pergolide may increase the vasoconstricting activities of Ergometrine and Ergometrine may increase the severity of adverse effects when combined with Diethylstilbestrol
|
DB00402
|
DB01198
| 397 | 542 |
Eszopiclone
|
Zopiclone
|
Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia. One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004.
|
Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
|
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Zopiclone.
| 48 |
[
[
[
397,
71,
542
]
],
[
[
397,
6,
6293
],
[
6293,
160,
542
]
],
[
[
397,
7,
9749
],
[
9749,
161,
542
]
],
[
[
397,
10,
17078
],
[
17078,
164,
542
]
],
[
[
397,
18,
7509
],
[
7509,
172,
542
]
],
[
[
397,
21,
28410
],
[
28410,
175,
542
]
],
[
[
397,
180,
171
],
[
171,
26,
542
]
],
[
[
397,
184,
674
],
[
674,
30,
542
]
],
[
[
397,
38,
1265
],
[
1265,
192,
542
]
],
[
[
397,
192,
491
],
[
491,
38,
542
]
]
] |
[
[
[
"Eszopiclone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} (Compound) binds {v} (Gene)",
"GABRA3"
],
[
"GABRA3",
"{u} (Gene) is bound by {v} (Compound)",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} (Compound) upregulates {v} (Gene)",
"GLI2"
],
[
"GLI2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} (Compound) palliates {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is palliated by {v} (Compound)",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} (Compound) downregulates {v} (Gene)",
"NVL"
],
[
"NVL",
"{u} (Gene) is downregulated by {v} (Compound)",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} (Compound) causes {v} (Side Effect)",
"Malaise"
],
[
"Malaise",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Zopiclone"
]
],
[
[
"Eszopiclone",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zopiclone"
]
]
] |
Eszopiclone (Compound) binds GABRA3 (Gene) and GABRA3 (Gene) is bound by Zopiclone (Compound)
Eszopiclone (Compound) upregulates GLI2 (Gene) and GLI2 (Gene) is upregulated by Zopiclone (Compound)
Eszopiclone (Compound) palliates multiple sclerosis (Disease) and multiple sclerosis (Disease) is palliated by Zopiclone (Compound)
Eszopiclone (Compound) downregulates NVL (Gene) and NVL (Gene) is downregulated by Zopiclone (Compound)
Eszopiclone (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is caused by Zopiclone (Compound)
Eszopiclone can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Zopiclone
Eszopiclone can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Zopiclone
Eszopiclone may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Zopiclone
Eszopiclone may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Zopiclone
|
DB01127
|
DB00653
| 1,162 | 405 |
Econazole
|
Magnesium sulfate
|
A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
|
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
|
The risk or severity of adverse effects can be increased when Econazole is combined with Magnesium sulfate.
| 48 |
[
[
[
1162,
71,
405
]
],
[
[
1162,
71,
434
],
[
434,
38,
405
]
],
[
[
1162,
223,
254
],
[
254,
38,
405
]
],
[
[
1162,
71,
605
],
[
605,
71,
405
]
],
[
[
1162,
249,
307
],
[
307,
225,
405
]
],
[
[
1162,
1,
1163
],
[
1163,
71,
405
]
],
[
[
1162,
155,
430
],
[
430,
71,
405
]
],
[
[
1162,
223,
198
],
[
198,
71,
405
]
],
[
[
1162,
251,
150
],
[
150,
95,
405
]
],
[
[
1162,
249,
142
],
[
142,
95,
405
]
]
] |
[
[
[
"Econazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} may decrease the metabolism of {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cilnidipine"
],
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} may increase the serum concentration of {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} (Compound) resembles {v} (Compound)",
"Butoconazole"
],
[
"Butoconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} (Compound) resembles {v} (Compound)",
"Oxiconazole"
],
[
"Oxiconazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} may decrease the metabolism of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may increase the serum concentration of {v}",
"Magnesium sulfate"
]
],
[
[
"Econazole",
"{u} may increase the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may increase the serum concentration of {v}",
"Magnesium sulfate"
]
]
] |
Econazole may increase the severity of adverse effects when combined with Flunarizine and Flunarizine may increase the central nervous system depressant activities of Magnesium sulfate
Econazole may decrease the metabolism of Buspirone and Buspirone may increase the central nervous system depressant activities of Magnesium sulfate
Econazole may increase the severity of adverse effects when combined with Cilnidipine and Cilnidipine may increase the severity of adverse effects when combined with Magnesium sulfate
Econazole may increase the serum concentration of Fluvastatin and Fluvastatin may increase the severity of adverse effects when combined with Magnesium sulfate
Econazole (Compound) resembles Butoconazole (Compound) and Butoconazole may increase the severity of adverse effects when combined with Magnesium sulfate
Econazole (Compound) resembles Oxiconazole (Compound) and Oxiconazole may increase the severity of adverse effects when combined with Magnesium sulfate
Econazole may decrease the metabolism of Cyclosporine and Cyclosporine may increase the severity of adverse effects when combined with Magnesium sulfate
Econazole may decrease the serum concentration of Fosphenytoin and Fosphenytoin may increase the serum concentration of Magnesium sulfate
Econazole may increase the serum concentration of Phenytoin and Phenytoin may increase the serum concentration of Magnesium sulfate
|
DB01429
|
DB00264
| 1,424 | 576 |
Aprindine
|
Metoprolol
|
Aprindine is a cardiac depressant used in arrhythmias.
|
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.
|
The metabolism of Metoprolol can be decreased when combined with Aprindine.
| 46 |
[
[
[
1424,
69,
576
]
],
[
[
1424,
69,
1037
],
[
1037,
249,
576
]
],
[
[
1424,
6,
18777
],
[
18777,
160,
576
]
],
[
[
1424,
1,
1639
],
[
1639,
249,
576
]
],
[
[
1424,
95,
1098
],
[
1098,
249,
576
]
],
[
[
1424,
118,
438
],
[
438,
249,
576
]
],
[
[
1424,
155,
262
],
[
262,
249,
576
]
],
[
[
1424,
69,
1037
],
[
1037,
71,
504
],
[
504,
249,
576
]
],
[
[
1424,
6,
18777
],
[
18777,
160,
504
],
[
504,
249,
576
]
],
[
[
1424,
69,
63
],
[
63,
223,
504
],
[
504,
249,
576
]
]
] |
[
[
[
"Aprindine",
"{u} may decrease the metabolism of {v}",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} may decrease the metabolism of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} (Compound) resembles {v} (Compound) and {u} may decrease the metabolism of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} (Compound) resembles {v} (Compound)",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} may decrease the metabolism of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Propranolol"
],
[
"Propranolol",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
],
[
[
"Aprindine",
"{u} may decrease the metabolism of {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may decrease the metabolism of {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
]
] |
Aprindine may decrease the metabolism of Betaxolol and Betaxolol may increase the serum concentration of Metoprolol
Aprindine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoprolol (Compound)
Aprindine (Compound) resembles Tripelennamine (Compound) and Tripelennamine may increase the serum concentration of Metoprolol
Aprindine may increase the serum concentration of Panobinostat and Panobinostat may increase the serum concentration of Metoprolol
Aprindine (Compound) resembles Imipramine (Compound) and Aprindine may decrease the metabolism of Imipramine and Imipramine may increase the serum concentration of Metoprolol
Aprindine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may increase the serum concentration of Metoprolol
Aprindine may decrease the metabolism of Betaxolol and Betaxolol may increase the severity of adverse effects when combined with Propranolol and Propranolol may increase the serum concentration of Metoprolol
Aprindine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Propranolol (Compound) and Propranolol may increase the serum concentration of Metoprolol
Aprindine may decrease the metabolism of Tranylcypromine and Tranylcypromine may decrease the metabolism of Propranolol and Propranolol may increase the serum concentration of Metoprolol
|
DB00409
|
DB01159
| 920 | 522 |
Remoxipride
|
Halothane
|
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
|
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
|
The risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane.
| 48 |
[
[
[
920,
71,
522
]
],
[
[
920,
6,
18777
],
[
18777,
160,
522
]
],
[
[
920,
69,
173
],
[
173,
26,
522
]
],
[
[
920,
225,
164
],
[
164,
26,
522
]
],
[
[
920,
71,
161
],
[
161,
26,
522
]
],
[
[
920,
184,
674
],
[
674,
30,
522
]
],
[
[
920,
192,
587
],
[
587,
38,
522
]
],
[
[
920,
38,
702
],
[
702,
192,
522
]
],
[
[
920,
71,
968
],
[
968,
206,
522
]
],
[
[
920,
54,
1046
],
[
1046,
208,
522
]
]
] |
[
[
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Halothane"
]
],
[
[
"Remoxipride",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Halothane"
]
]
] |
Remoxipride (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halothane (Compound)
Remoxipride may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Halothane
Remoxipride may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital can increase the metabolism of Halothane
Remoxipride may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Halothane
Remoxipride can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Halothane
Remoxipride may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Halothane
Remoxipride may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Halothane
Remoxipride may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Halothane
Remoxipride may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Halothane
|
DB01037
|
DB00409
| 39 | 920 |
Selegiline
|
Remoxipride
|
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
|
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
|
The risk or severity of adverse effects can be increased when Selegiline is combined with Remoxipride.
| 48 |
[
[
[
39,
71,
920
]
],
[
[
39,
71,
980
],
[
980,
58,
920
]
],
[
[
39,
6,
18777
],
[
18777,
160,
920
]
],
[
[
39,
71,
679
],
[
679,
38,
920
]
],
[
[
39,
225,
491
],
[
491,
38,
920
]
],
[
[
39,
225,
1265
],
[
1265,
192,
920
]
],
[
[
39,
71,
702
],
[
702,
192,
920
]
],
[
[
39,
82,
1046
],
[
1046,
208,
920
]
],
[
[
39,
71,
997
],
[
997,
57,
920
]
],
[
[
39,
82,
1037
],
[
1037,
223,
920
]
]
] |
[
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Remoxipride"
]
],
[
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the metabolism of {v}",
"Remoxipride"
]
]
] |
Selegiline may increase the severity of adverse effects when combined with Amisulpride and Amisulpride may increase the antipsychotic activities of Remoxipride
Selegiline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Remoxipride (Compound)
Selegiline may increase the severity of adverse effects when combined with Thalidomide and Thalidomide may increase the central nervous system depressant activities of Remoxipride
Selegiline may increase the severity of adverse effects when combined with Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Remoxipride
Selegiline may increase the severity of adverse effects when combined with Nabilone and Nabilone may increase the central nervous system depressant activities of Remoxipride
Selegiline may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the central nervous system depressant activities of Remoxipride
Selegiline may increase the hypotensive activities of Metyrosine and Metyrosine may increase the sedative activities of Remoxipride
Selegiline may increase the severity of adverse effects when combined with Lithium cation and Lithium cation may increase the neurotoxic activities of Remoxipride
Selegiline may increase the hypotensive activities of Betaxolol and Betaxolol may decrease the metabolism of Remoxipride
|
DB09027
|
DB00796
| 1,659 | 304 |
Ledipasvir
|
Candesartan cilexetil
|
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as ledipasvir. More specifically, ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural Protein 5A (NS5A), which is required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required
|
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for
|
The serum concentration of Candesartan cilexetil can be increased when it is combined with Ledipasvir.
| 72 |
[
[
[
1659,
95,
304
]
],
[
[
1659,
251,
147
],
[
147,
26,
304
]
],
[
[
1659,
251,
451
],
[
451,
223,
304
]
],
[
[
1659,
95,
795
],
[
795,
223,
304
]
],
[
[
1659,
95,
461
],
[
461,
71,
304
]
],
[
[
1659,
95,
516
],
[
516,
225,
304
]
],
[
[
1659,
251,
925
],
[
925,
71,
304
]
],
[
[
1659,
95,
1437
],
[
1437,
232,
304
]
],
[
[
1659,
95,
39
],
[
39,
82,
304
]
],
[
[
1659,
95,
190
],
[
190,
236,
304
]
]
] |
[
[
[
"Ledipasvir",
"{u} may increase the serum concentration of {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may decrease the serum concentration of {v}",
"Omeprazole"
],
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may increase the serum concentration of {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may decrease the metabolism of {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may increase the serum concentration of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may increase the serum concentration of {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may decrease the serum concentration of {v}",
"Reserpine"
],
[
"Reserpine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may increase the serum concentration of {v}",
"Tolvaptan"
],
[
"Tolvaptan",
"{u} may increase the hypotensive effects when combined with {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may increase the serum concentration of {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Candesartan cilexetil"
]
],
[
[
"Ledipasvir",
"{u} may increase the serum concentration of {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may increase the hypotensive activities of {v}",
"Candesartan cilexetil"
]
]
] |
Ledipasvir may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Candesartan cilexetil
Ledipasvir may decrease the serum concentration of Omeprazole and Omeprazole may decrease the metabolism of Candesartan cilexetil
Ledipasvir may increase the serum concentration of Ticagrelor and Ticagrelor may decrease the metabolism of Candesartan cilexetil
Ledipasvir may increase the serum concentration of Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Candesartan cilexetil
Ledipasvir may increase the serum concentration of Felodipine and Felodipine may increase the severity of adverse effects when combined with Candesartan cilexetil
Ledipasvir may decrease the serum concentration of Reserpine and Reserpine may increase the severity of adverse effects when combined with Candesartan cilexetil
Ledipasvir may increase the serum concentration of Tolvaptan and Tolvaptan may increase the hypotensive effects when combined with Candesartan cilexetil
Ledipasvir may increase the serum concentration of Selegiline and Selegiline may increase the hypotensive activities of Candesartan cilexetil
Ledipasvir may increase the serum concentration of Bepridil and Bepridil may increase the hypotensive activities of Candesartan cilexetil
|
DB05294
|
DB01236
| 1,185 | 354 |
Vandetanib
|
Sevoflurane
|
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
|
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.
|
Vandetanib may increase the QTc-prolonging activities of Sevoflurane.
| 19 |
[
[
[
1185,
42,
354
]
],
[
[
1185,
42,
1313
],
[
1313,
42,
354
]
],
[
[
1185,
6,
4590
],
[
4590,
160,
354
]
],
[
[
1185,
21,
28495
],
[
28495,
175,
354
]
],
[
[
1185,
251,
171
],
[
171,
26,
354
]
],
[
[
1185,
42,
1262
],
[
1262,
192,
354
]
],
[
[
1185,
209,
589
],
[
589,
42,
354
]
],
[
[
1185,
55,
539
],
[
539,
42,
354
]
],
[
[
1185,
69,
575
],
[
575,
42,
354
]
],
[
[
1185,
95,
1019
],
[
1019,
196,
354
]
]
] |
[
[
[
"Vandetanib",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} may increase the QTc prolonging activities of {v}",
"Perflutren"
],
[
"Perflutren",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} may decrease the serum concentration of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
]
],
[
[
"Vandetanib",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
]
]
] |
Vandetanib may increase the QTc prolonging activities of Perflutren and Perflutren may increase the QTc prolonging activities of Sevoflurane
Vandetanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Vandetanib (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Sevoflurane (Compound)
Vandetanib may decrease the serum concentration of Pentobarbital and Pentobarbital can increase the metabolism of Sevoflurane
Vandetanib may increase the QTc prolonging activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Sevoflurane
Vandetanib may increase the severity of QTc prolonging effects when combined with Disopyramide and Disopyramide may increase the QTc prolonging activities of Sevoflurane
Vandetanib may increase the severity of QTc prolonging effects when combined with Artemether and Artemether may increase the QTc prolonging activities of Sevoflurane
Vandetanib may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Sevoflurane
Vandetanib may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Sevoflurane
|
DB09183
|
DB08933
| 661 | 1,114 |
Dasabuvir
|
Luliconazole
|
Dasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Dasabuvir. Dasabuvir is a non-nucleoside NS5B inhibitor which binds to the palm domain of NS5B and induces a conformational change which renders the polymerase unable to elongate viral RNA [FDA Label]. The binding sites for non-nucleoside NS5B inhibitors are poorly conserved across HCV genotypes leading to the restriction of Dasabuvir's
|
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
|
The serum concentration of Luliconazole can be increased when it is combined with Dasabuvir.
| 72 |
[
[
[
661,
95,
1114
]
],
[
[
661,
69,
411
],
[
411,
95,
1114
]
],
[
[
661,
249,
198
],
[
198,
95,
1114
]
],
[
[
661,
180,
171
],
[
171,
95,
1114
]
],
[
[
661,
251,
1110
],
[
1110,
95,
1114
]
],
[
[
661,
95,
1019
],
[
1019,
95,
1114
]
],
[
[
661,
69,
411
],
[
411,
6,
4590
],
[
4590,
160,
1114
]
],
[
[
661,
249,
198
],
[
198,
6,
4590
],
[
4590,
160,
1114
]
],
[
[
661,
69,
422
],
[
422,
223,
163
],
[
163,
225,
1114
]
],
[
[
661,
69,
1085
],
[
1085,
225,
1303
],
[
1303,
71,
1114
]
]
] |
[
[
[
"Dasabuvir",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} may decrease the metabolism of {v}",
"Sertraline"
],
[
"Sertraline",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} may decrease the serum concentration of {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} may decrease the metabolism of {v}",
"Sertraline"
],
[
"Sertraline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may decrease the metabolism of {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Luliconazole"
]
],
[
[
"Dasabuvir",
"{u} may decrease the metabolism of {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Luliconazole"
]
]
] |
Dasabuvir may decrease the metabolism of Sertraline and Sertraline may increase the serum concentration of Luliconazole
Dasabuvir may increase the serum concentration of Cyclosporine and Cyclosporine may increase the serum concentration of Luliconazole
Dasabuvir can increase the metabolism of Pentobarbital and Pentobarbital may increase the serum concentration of Luliconazole
Dasabuvir may decrease the serum concentration of Enzalutamide and Enzalutamide may increase the serum concentration of Luliconazole
Dasabuvir may increase the serum concentration of Mifepristone and Mifepristone may increase the serum concentration of Luliconazole
Dasabuvir may decrease the metabolism of Sertraline and Sertraline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Luliconazole (Compound)
Dasabuvir may increase the serum concentration of Cyclosporine and Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Luliconazole (Compound)
Dasabuvir may decrease the metabolism of Midostaurin and Midostaurin may decrease the metabolism of Oxycodone and Oxycodone may increase the severity of adverse effects when combined with Luliconazole
Dasabuvir may decrease the metabolism of Olaparib and Olaparib may increase the severity of adverse effects when combined with Methylergometrine and Methylergometrine may increase the severity of adverse effects when combined with Luliconazole
|
DB00852
|
DB13595
| 718 | 89 |
Pseudoephedrine
|
Almasilate
|
Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927.
|
Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids. Given that there are generally more widely available conventional antacids that are just as - if not more - effective than almasilate, almasilate products are only available in certain parts of Europe and/or Asia.
|
Pseudoephedrine may decrease the excretion rate of Almasilate which could result in a higher serum level.
| 71 |
[
[
[
718,
94,
89
]
],
[
[
718,
83,
1379
],
[
1379,
89,
89
]
],
[
[
718,
69,
653
],
[
653,
89,
89
]
],
[
[
718,
98,
1448
],
[
1448,
89,
89
]
],
[
[
718,
251,
1506
],
[
1506,
246,
89
]
],
[
[
718,
69,
59
],
[
59,
94,
89
]
],
[
[
718,
225,
707
],
[
707,
94,
89
]
],
[
[
718,
69,
640
],
[
640,
95,
89
]
],
[
[
718,
83,
18
],
[
18,
251,
89
]
],
[
[
718,
69,
508
],
[
508,
251,
89
]
]
] |
[
[
[
"Pseudoephedrine",
"{u} may decrease the excretion rate {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the stimulatory activities of {v}",
"Periciazine"
],
[
"Periciazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the sedative activities of {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the serum concentration of {v}",
"Methenamine"
],
[
"Methenamine",
"{u} may decrease the therapeutic efficacy of {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the metabolism of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may decrease the excretion rate {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may decrease the excretion rate {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the metabolism of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the serum concentration of {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the stimulatory activities of {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may decrease the serum concentration of {v}",
"Almasilate"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may decrease the serum concentration of {v}",
"Almasilate"
]
]
] |
Pseudoephedrine may decrease the stimulatory activities of Periciazine and Periciazine may decrease the absorption and serum concentration of Almasilate
Pseudoephedrine may decrease the metabolism of Thioridazine and Thioridazine may decrease the absorption and serum concentration of Almasilate
Pseudoephedrine may decrease the sedative activities of Alimemazine and Alimemazine may decrease the absorption and serum concentration of Almasilate
Pseudoephedrine may decrease the serum concentration of Methenamine and Methenamine may decrease the therapeutic efficacy of Almasilate
Pseudoephedrine may decrease the metabolism of Quinidine and Quinidine may decrease the excretion rate Almasilate
Pseudoephedrine may increase the severity of adverse effects when combined with Mephentermine and Mephentermine may decrease the excretion rate Almasilate
Pseudoephedrine may decrease the metabolism of Quinine and Quinine may increase the serum concentration of Almasilate
Pseudoephedrine may decrease the stimulatory activities of Sulpiride and Sulpiride may decrease the serum concentration of Almasilate
Pseudoephedrine may decrease the metabolism of Delavirdine and Delavirdine may decrease the serum concentration of Almasilate
|
DB00204
|
DB01356
| 614 | 997 |
Dofetilide
|
Lithium cation
|
Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
|
Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
|
Dofetilide may increase the QTc-prolonging activities of Lithium cation.
| 19 |
[
[
[
614,
42,
997
]
],
[
[
614,
21,
28392
],
[
28392,
175,
997
]
],
[
[
614,
42,
1262
],
[
1262,
192,
997
]
],
[
[
614,
55,
1027
],
[
1027,
42,
997
]
],
[
[
614,
104,
501
],
[
501,
42,
997
]
],
[
[
614,
42,
884
],
[
884,
42,
997
]
],
[
[
614,
95,
1088
],
[
1088,
42,
997
]
],
[
[
614,
251,
495
],
[
495,
55,
997
]
],
[
[
614,
42,
932
],
[
932,
211,
997
]
],
[
[
614,
95,
270
],
[
270,
211,
997
]
]
] |
[
[
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} may increase the arrhythmogenic activities of {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} may increase the serum concentration of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} may decrease the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
]
],
[
[
"Dofetilide",
"{u} may increase the serum concentration of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
]
]
] |
Dofetilide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Lithium cation (Compound)
Dofetilide may increase the QTc prolonging activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Lithium cation
Dofetilide may increase the severity of QTc prolonging effects when combined with Sotalol and Sotalol may increase the QTc prolonging activities of Lithium cation
Dofetilide may increase the arrhythmogenic activities of Saquinavir and Saquinavir may increase the QTc prolonging activities of Lithium cation
Dofetilide may increase the QTc prolonging activities of Levofloxacin and Levofloxacin may increase the QTc prolonging activities of Lithium cation
Dofetilide may increase the serum concentration of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Lithium cation
Dofetilide may decrease the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Lithium cation
Dofetilide may increase the QTc prolonging activities of Aripiprazole and Aripiprazole may increase the neurotoxic activities of Lithium cation
Dofetilide may increase the serum concentration of Prochlorperazine and Prochlorperazine may increase the neurotoxic activities of Lithium cation
|
DB00831
|
DB01595
| 940 | 442 |
Trifluoperazine
|
Nitrazepam
|
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
|
A benzodiazepine derivative used as an anticonvulsant and hypnotic.
|
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrazepam.
| 48 |
[
[
[
940,
71,
442
]
],
[
[
940,
225,
312
],
[
312,
1,
442
]
],
[
[
940,
225,
407
],
[
407,
71,
442
]
],
[
[
940,
71,
273
],
[
273,
155,
442
]
],
[
[
940,
71,
275
],
[
275,
71,
442
]
],
[
[
940,
6,
8339
],
[
8339,
160,
442
]
],
[
[
940,
21,
28408
],
[
28408,
175,
442
]
],
[
[
940,
71,
164
],
[
164,
26,
442
]
],
[
[
940,
225,
171
],
[
171,
26,
442
]
],
[
[
940,
192,
679
],
[
679,
38,
442
]
]
] |
[
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temazepam"
],
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diazepam"
],
[
"Diazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dantrolene"
],
[
"Dantrolene",
"{u} (Compound) resembles {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Estazolam"
],
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Nitrazepam"
]
],
[
[
"Trifluoperazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Nitrazepam"
]
]
] |
Trifluoperazine may increase the severity of adverse effects when combined with Temazepam and Temazepam (Compound) resembles Nitrazepam (Compound)
Trifluoperazine may increase the severity of adverse effects when combined with Diazepam and Diazepam may increase the severity of adverse effects when combined with Nitrazepam
Trifluoperazine may increase the severity of adverse effects when combined with Dantrolene and Dantrolene (Compound) resembles Nitrazepam (Compound)
Trifluoperazine may increase the severity of adverse effects when combined with Estazolam and Estazolam may increase the severity of adverse effects when combined with Nitrazepam
Trifluoperazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nitrazepam (Compound)
Trifluoperazine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Nitrazepam (Compound)
Trifluoperazine may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital can increase the metabolism of Nitrazepam
Trifluoperazine may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Nitrazepam
Trifluoperazine may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Nitrazepam
|
DB01010
|
DB00809
| 1,290 | 70 |
Edrophonium
|
Tropicamide
|
A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
|
Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors. Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia for eye exams or ocular procedures. It is also used in combination with [hydroxyamphetamine] for the same indication. Oral tropicamide has been investigated as a potential drug to relieve sialorrhea in patients with Parkinson's Disease.
|
The therapeutic efficacy of Tropicamide can be decreased when used in combination with Edrophonium.
| 69 |
[
[
[
1290,
92,
70
]
],
[
[
1290,
21,
28396
],
[
28396,
175,
70
]
],
[
[
1290,
92,
26
],
[
26,
24,
70
]
],
[
[
1290,
92,
72
],
[
72,
225,
70
]
],
[
[
1290,
92,
62
],
[
62,
71,
70
]
],
[
[
1290,
155,
1292
],
[
1292,
92,
70
]
],
[
[
1290,
21,
28396
],
[
28396,
175,
211
],
[
211,
1,
70
]
],
[
[
1290,
21,
28676
],
[
28676,
175,
26
],
[
26,
24,
70
]
],
[
[
1290,
92,
26
],
[
26,
6,
8167
],
[
8167,
160,
70
]
],
[
[
1290,
92,
72
],
[
72,
155,
294
],
[
294,
1,
70
]
]
] |
[
[
[
"Edrophonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} (Compound) resembles {v} (Compound)",
"Neostigmine"
],
[
"Neostigmine",
"{u} may decrease the therapeutic efficacy of {v}",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Dysphagia"
],
[
"Dysphagia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Tropicamide"
]
],
[
[
"Edrophonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Tropicamide"
]
]
] |
Edrophonium (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Tropicamide (Compound)
Edrophonium may decrease the therapeutic efficacy of Tiotropium and Tiotropium may increase the anticholinergic activities of Tropicamide
Edrophonium may decrease the therapeutic efficacy of Orphenadrine and Orphenadrine may increase the severity of adverse effects when combined with Tropicamide
Edrophonium may decrease the therapeutic efficacy of Trihexyphenidyl and Trihexyphenidyl may increase the severity of adverse effects when combined with Tropicamide
Edrophonium (Compound) resembles Neostigmine (Compound) and Neostigmine may decrease the therapeutic efficacy of Tropicamide
Edrophonium (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Ketoprofen (Compound) and Ketoprofen (Compound) resembles Tropicamide (Compound)
Edrophonium (Compound) causes Dysphagia (Side Effect) and Dysphagia (Side Effect) is caused by Tiotropium (Compound) and Tiotropium may increase the anticholinergic activities of Tropicamide
Edrophonium may decrease the therapeutic efficacy of Tiotropium and Tiotropium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Tropicamide (Compound)
Edrophonium may decrease the therapeutic efficacy of Orphenadrine and Orphenadrine (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine (Compound) resembles Tropicamide (Compound)
|
DB08899
|
DB08868
| 1,110 | 340 |
Enzalutamide
|
Fingolimod
|
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile,
|
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
|
The serum concentration of Fingolimod can be decreased when it is combined with Enzalutamide.
| 74 |
[
[
[
1110,
97,
340
]
],
[
[
1110,
6,
18777
],
[
18777,
160,
340
]
],
[
[
1110,
21,
28506
],
[
28506,
175,
340
]
],
[
[
1110,
251,
177
],
[
177,
26,
340
]
],
[
[
1110,
97,
173
],
[
173,
26,
340
]
],
[
[
1110,
97,
971
],
[
971,
42,
340
]
],
[
[
1110,
95,
1019
],
[
1019,
196,
340
]
],
[
[
1110,
249,
653
],
[
653,
42,
340
]
],
[
[
1110,
97,
82
],
[
82,
56,
340
]
],
[
[
1110,
95,
1099
],
[
1099,
56,
340
]
]
] |
[
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the QTc prolonging activities of {v}",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the QTc prolonging activities of {v}",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} may decrease the serum concentration of {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may increase the immunosuppressive activities of {v}",
"Fingolimod"
]
],
[
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may increase the immunosuppressive activities of {v}",
"Fingolimod"
]
]
] |
Enzalutamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Enzalutamide (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Fingolimod (Compound)
Enzalutamide may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Fingolimod
Enzalutamide may decrease the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Fingolimod
Enzalutamide may decrease the serum concentration of Zuclopenthixol and Zuclopenthixol may increase the QTc prolonging activities of Fingolimod
Enzalutamide may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Fingolimod
Enzalutamide may increase the serum concentration of Thioridazine and Thioridazine may increase the QTc prolonging activities of Fingolimod
Enzalutamide may decrease the serum concentration of Prednisolone and Prednisolone may increase the immunosuppressive activities of Fingolimod
Enzalutamide may increase the serum concentration of Idelalisib and Idelalisib may increase the immunosuppressive activities of Fingolimod
|
DB00420
|
DB06724
| 288 | 86 |
Promazine
|
Calcium carbonate
|
A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.
|
Calcium carbonate is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. Calcium carbonate may also be used as a nutritional supplement or to treat hypocalcemia.
|
Promazine can cause a decrease in the absorption of Calcium carbonate resulting in a reduced serum concentration and potentially a decrease in efficacy.
| 66 |
[
[
[
288,
89,
86
]
],
[
[
288,
1,
1448
],
[
1448,
89,
86
]
],
[
[
288,
196,
884
],
[
884,
89,
86
]
],
[
[
288,
249,
653
],
[
653,
89,
86
]
],
[
[
288,
272,
525
],
[
525,
89,
86
]
],
[
[
288,
155,
940
],
[
940,
89,
86
]
],
[
[
288,
95,
755
],
[
755,
89,
86
]
],
[
[
288,
69,
1093
],
[
1093,
89,
86
]
],
[
[
288,
223,
990
],
[
990,
89,
86
]
],
[
[
288,
89,
78
],
[
78,
246,
86
]
]
] |
[
[
[
"Promazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} may increase the QTc prolonging activities of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound) and {u} may decrease the metabolism of {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} may decrease the metabolism of {v}",
"Mesoridazine"
],
[
"Mesoridazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Calcium carbonate"
]
],
[
[
"Promazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
],
[
"Bismuth subcitrate potassium",
"{u} may decrease the therapeutic efficacy of {v}",
"Calcium carbonate"
]
]
] |
Promazine (Compound) resembles Alimemazine (Compound) and Alimemazine may decrease the absorption and serum concentration of Calcium carbonate
Promazine may increase the QTc prolonging activities of Levofloxacin and Levofloxacin may decrease the absorption and serum concentration of Calcium carbonate
Promazine may increase the serum concentration of Thioridazine and Thioridazine may decrease the absorption and serum concentration of Calcium carbonate
Promazine (Compound) resembles Perphenazine (Compound) and Promazine may decrease the metabolism of Perphenazine and Perphenazine may decrease the absorption and serum concentration of Calcium carbonate
Promazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may decrease the absorption and serum concentration of Calcium carbonate
Promazine may increase the serum concentration of Doxycycline and Doxycycline may decrease the absorption and serum concentration of Calcium carbonate
Promazine may decrease the metabolism of Isoniazid and Isoniazid may decrease the absorption and serum concentration of Calcium carbonate
Promazine may decrease the metabolism of Mesoridazine and Mesoridazine may decrease the absorption and serum concentration of Calcium carbonate
Promazine may decrease the absorption and serum concentration of Bismuth subcitrate potassium and Bismuth subcitrate potassium may decrease the therapeutic efficacy of Calcium carbonate
|
DB00312
|
DB00381
| 171 | 385 |
Pentobarbital
|
Amlodipine
|
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
|
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
|
The metabolism of Amlodipine can be increased when combined with Pentobarbital.
| 3 |
[
[
[
171,
26,
385
]
],
[
[
171,
26,
516
],
[
516,
225,
385
]
],
[
[
171,
97,
503
],
[
503,
225,
385
]
],
[
[
171,
97,
512
],
[
512,
1,
385
]
],
[
[
171,
6,
15394
],
[
15394,
160,
385
]
],
[
[
171,
21,
28924
],
[
28924,
175,
385
]
],
[
[
171,
116,
164
],
[
164,
26,
385
]
],
[
[
171,
180,
177
],
[
177,
26,
385
]
],
[
[
171,
26,
147
],
[
147,
26,
385
]
],
[
[
171,
26,
344
],
[
344,
32,
385
]
]
] |
[
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} may decrease the serum concentration of {v}",
"Nimodipine"
],
[
"Nimodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} may decrease the serum concentration of {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Angioedema"
],
[
"Angioedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Amlodipine"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Udenafil"
],
[
"Udenafil",
"{u} may increase the antihypertensive activities of {v}",
"Amlodipine"
]
]
] |
Pentobarbital can increase the metabolism of Felodipine and Felodipine may increase the severity of adverse effects when combined with Amlodipine
Pentobarbital may decrease the serum concentration of Nimodipine and Nimodipine may increase the severity of adverse effects when combined with Amlodipine
Pentobarbital may decrease the serum concentration of Nisoldipine and Nisoldipine (Compound) resembles Amlodipine (Compound)
Pentobarbital (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Amlodipine (Compound)
Pentobarbital (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Amlodipine (Compound)
Pentobarbital (Compound) resembles Phenobarbital (Compound) and Pentobarbital may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital can increase the metabolism of Amlodipine
Pentobarbital can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Amlodipine
Pentobarbital can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Amlodipine
Pentobarbital can increase the metabolism of Udenafil and Udenafil may increase the antihypertensive activities of Amlodipine
|
DB01232
|
DB06695
| 501 | 677 |
Saquinavir
|
Dabigatran etexilate
|
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351]
|
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran].[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. Dabigatran etexilate was approved by the FDA in 2010.
|
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Saquinavir.
| 76 |
[
[
[
501,
99,
677
]
],
[
[
501,
6,
8339
],
[
8339,
160,
677
]
],
[
[
501,
21,
28401
],
[
28401,
175,
677
]
],
[
[
501,
180,
156
],
[
156,
26,
677
]
],
[
[
501,
251,
654
],
[
654,
182,
677
]
],
[
[
501,
249,
219
],
[
219,
182,
677
]
],
[
[
501,
196,
784
],
[
784,
182,
677
]
],
[
[
501,
42,
689
],
[
689,
182,
677
]
],
[
[
501,
223,
364
],
[
364,
182,
677
]
],
[
[
501,
249,
744
],
[
744,
28,
677
]
]
] |
[
[
[
"Saquinavir",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} may decrease the serum concentration of {v}",
"Tipranavir"
],
[
"Tipranavir",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} may increase the serum concentration of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} may decrease the metabolism of {v}",
"Etoricoxib"
],
[
"Etoricoxib",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
]
],
[
[
"Saquinavir",
"{u} may increase the serum concentration of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
]
]
] |
Saquinavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabigatran etexilate (Compound)
Saquinavir (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Dabigatran etexilate (Compound)
Saquinavir can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Dabigatran etexilate
Saquinavir may decrease the serum concentration of Tipranavir and Tipranavir may increase the anticoagulant activities of Dabigatran etexilate
Saquinavir may increase the serum concentration of Warfarin and Warfarin may increase the anticoagulant activities of Dabigatran etexilate
Saquinavir may increase the QTc prolonging activities of Anagrelide and Anagrelide may increase the anticoagulant activities of Dabigatran etexilate
Saquinavir may increase the QTc prolonging activities of Treprostinil and Treprostinil may increase the anticoagulant activities of Dabigatran etexilate
Saquinavir may decrease the metabolism of Etoricoxib and Etoricoxib may increase the anticoagulant activities of Dabigatran etexilate
Saquinavir may increase the serum concentration of Edoxaban and Edoxaban may increase the anticoagulant activities of Dabigatran etexilate
|
DB00872
|
DB00690
| 531 | 565 |
Conivaptan
|
Flurazepam
|
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
|
A benzodiazepine derivative used mainly as a hypnotic.
|
The serum concentration of Flurazepam can be increased when it is combined with Conivaptan.
| 72 |
[
[
[
531,
95,
565
]
],
[
[
531,
95,
499
],
[
499,
225,
565
]
],
[
[
531,
95,
603
],
[
603,
1,
565
]
],
[
[
531,
95,
588
],
[
588,
155,
565
]
],
[
[
531,
6,
4590
],
[
4590,
160,
565
]
],
[
[
531,
21,
28392
],
[
28392,
175,
565
]
],
[
[
531,
180,
164
],
[
164,
26,
565
]
],
[
[
531,
95,
173
],
[
173,
26,
565
]
],
[
[
531,
249,
1083
],
[
1083,
38,
565
]
],
[
[
531,
95,
72
],
[
72,
38,
565
]
]
] |
[
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Adinazolam"
],
[
"Adinazolam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Flurazepam"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Flurazepam"
]
]
] |
Conivaptan may increase the serum concentration of Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Flurazepam
Conivaptan may increase the serum concentration of Adinazolam and Adinazolam (Compound) resembles Flurazepam (Compound)
Conivaptan may increase the serum concentration of Chloroquine and Chloroquine (Compound) resembles Flurazepam (Compound)
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Flurazepam (Compound)
Conivaptan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Flurazepam (Compound)
Conivaptan can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Flurazepam
Conivaptan may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Flurazepam
Conivaptan may increase the serum concentration of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Flurazepam
Conivaptan may increase the serum concentration of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Flurazepam
|
DB04908
|
DB01263
| 929 | 479 |
Flibanserin
|
Posaconazole
|
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
|
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
|
The serum concentration of Posaconazole can be increased when it is combined with Flibanserin.
| 72 |
[
[
[
929,
95,
479
]
],
[
[
929,
251,
161
],
[
161,
26,
479
]
],
[
[
929,
225,
1007
],
[
1007,
42,
479
]
],
[
[
929,
95,
1019
],
[
1019,
196,
479
]
],
[
[
929,
225,
610
],
[
610,
223,
479
]
],
[
[
929,
225,
336
],
[
336,
69,
479
]
],
[
[
929,
95,
501
],
[
501,
223,
479
]
],
[
[
929,
95,
352
],
[
352,
69,
479
]
],
[
[
929,
54,
471
],
[
471,
69,
479
]
],
[
[
929,
236,
587
],
[
587,
69,
479
]
]
] |
[
[
[
"Flibanserin",
"{u} may increase the serum concentration of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prazepam"
],
[
"Prazepam",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may increase the serum concentration of {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may increase the serum concentration of {v}",
"Estradiol"
],
[
"Estradiol",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Flibanserin",
"{u} may increase the hypotensive activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
]
] |
Flibanserin may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Posaconazole
Flibanserin may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the QTc prolonging activities of Posaconazole
Flibanserin may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Posaconazole
Flibanserin may increase the severity of adverse effects when combined with Atomoxetine and Atomoxetine may decrease the metabolism of Posaconazole
Flibanserin may increase the severity of adverse effects when combined with Prazepam and Prazepam may decrease the metabolism of Posaconazole
Flibanserin may increase the serum concentration of Saquinavir and Saquinavir may decrease the metabolism of Posaconazole
Flibanserin may increase the serum concentration of Estradiol and Estradiol may decrease the metabolism of Posaconazole
Flibanserin may increase the sedative activities of Rotigotine and Rotigotine may decrease the metabolism of Posaconazole
Flibanserin may increase the hypotensive activities of Ethanol and Ethanol may decrease the metabolism of Posaconazole
|
DB00390
|
DB00674
| 457 | 264 |
Digoxin
|
Galantamine
|
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
|
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and
|
Digoxin may increase the bradycardic activities of Galantamine.
| 53 |
[
[
[
457,
76,
264
]
],
[
[
457,
6,
4590
],
[
4590,
160,
264
]
],
[
[
457,
21,
28834
],
[
28834,
175,
264
]
],
[
[
457,
180,
164
],
[
164,
26,
264
]
],
[
[
457,
95,
640
],
[
640,
42,
264
]
],
[
[
457,
234,
863
],
[
863,
42,
264
]
],
[
[
457,
95,
1019
],
[
1019,
196,
264
]
],
[
[
457,
69,
143
],
[
143,
42,
264
]
],
[
[
457,
69,
267
],
[
267,
223,
264
]
],
[
[
457,
234,
422
],
[
422,
223,
264
]
]
] |
[
[
[
"Digoxin",
"{u} may increase the bradycardic activities of {v}",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Ventricular tachycardia"
],
[
"Ventricular tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} may increase the serum concentration of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the QTc prolonging activities of {v}",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Galantamine"
]
],
[
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may decrease the metabolism of {v}",
"Galantamine"
]
]
] |
Digoxin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Galantamine (Compound)
Digoxin (Compound) causes Ventricular tachycardia (Side Effect) and Ventricular tachycardia (Side Effect) is caused by Galantamine (Compound)
Digoxin can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Galantamine
Digoxin may increase the serum concentration of Quinine and Quinine may increase the QTc prolonging activities of Galantamine
Digoxin may decrease the cardiotoxic activities of Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Galantamine
Digoxin may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Galantamine
Digoxin may decrease the metabolism of Erythromycin and Erythromycin may increase the QTc prolonging activities of Galantamine
Digoxin may decrease the metabolism of Lovastatin and Lovastatin may decrease the metabolism of Galantamine
Digoxin may decrease the cardiotoxic activities of Midostaurin and Midostaurin may decrease the metabolism of Galantamine
|
DB01137
|
DB00270
| 884 | 472 |
Levofloxacin
|
Isradipine
|
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
|
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
|
Levofloxacin may increase the QTc-prolonging activities of Isradipine.
| 19 |
[
[
[
884,
42,
472
]
],
[
[
884,
6,
4590
],
[
4590,
160,
472
]
],
[
[
884,
21,
28945
],
[
28945,
175,
472
]
],
[
[
884,
42,
154
],
[
154,
32,
472
]
],
[
[
884,
42,
288
],
[
288,
42,
472
]
],
[
[
884,
249,
437
],
[
437,
42,
472
]
],
[
[
884,
196,
1091
],
[
1091,
42,
472
]
],
[
[
884,
42,
1019
],
[
1019,
196,
472
]
],
[
[
884,
185,
589
],
[
589,
42,
472
]
],
[
[
884,
275,
1210
],
[
1210,
42,
472
]
]
] |
[
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity reaction"
],
[
"Photosensitivity reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may increase the antihypertensive activities of {v}",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Promazine"
],
[
"Promazine",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} may increase the serum concentration of {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} may increase the hypoglycemic activities of {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
],
[
[
"Levofloxacin",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the QTc prolonging activities of {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Isradipine"
]
]
] |
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isradipine (Compound)
Levofloxacin (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Isradipine (Compound)
Levofloxacin may increase the QTc prolonging activities of Vardenafil and Vardenafil may increase the antihypertensive activities of Isradipine
Levofloxacin may increase the QTc prolonging activities of Promazine and Promazine may increase the QTc prolonging activities of Isradipine
Levofloxacin may increase the serum concentration of Pazopanib and Pazopanib may increase the QTc prolonging activities of Isradipine
Levofloxacin may increase the QTc prolonging activities of Dronedarone and Dronedarone may increase the QTc prolonging activities of Isradipine
Levofloxacin may increase the QTc prolonging activities of Mifepristone and Mifepristone may increase the QTc prolonging activities of Isradipine
Levofloxacin may increase the hypoglycemic activities of Disopyramide and Disopyramide may increase the QTc prolonging activities of Isradipine
Levofloxacin (Compound) resembles Ofloxacin (Compound) and Levofloxacin may increase the QTc prolonging activities of Ofloxacin and Ofloxacin may increase the QTc prolonging activities of Isradipine
|
DB13167
|
DB09095
| 796 | 100 |
Alclofenac
|
Difluocortolone
|
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
|
Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.
|
The risk or severity of adverse effects can be increased when Alclofenac is combined with Difluocortolone.
| 48 |
[
[
[
796,
71,
100
]
],
[
[
796,
225,
742
],
[
742,
71,
100
]
],
[
[
796,
49,
882
],
[
882,
225,
100
]
],
[
[
796,
71,
1351
],
[
1351,
71,
100
]
],
[
[
796,
71,
124
],
[
124,
249,
100
]
],
[
[
796,
51,
894
],
[
894,
259,
100
]
],
[
[
796,
92,
1066
],
[
1066,
259,
100
]
],
[
[
796,
225,
742
],
[
742,
182,
219
],
[
219,
28,
100
]
],
[
[
796,
225,
814
],
[
814,
97,
219
],
[
219,
28,
100
]
],
[
[
796,
49,
882
],
[
882,
89,
81
],
[
81,
25,
100
]
]
] |
[
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clonixin"
],
[
"Clonixin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may increase the neuroexcitatory activities of {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the serum concentration of {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may decrease the diuretic activities of {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may increase the hypokalemic activities of {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may decrease the therapeutic efficacy of {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may increase the hypokalemic activities of {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clonixin"
],
[
"Clonixin",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may decrease the serum concentration of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Difluocortolone"
]
],
[
[
"Alclofenac",
"{u} may increase the neuroexcitatory activities of {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may decrease the absorption and serum concentration of {v}",
"Tromethamine"
],
[
"Tromethamine",
"{u} can decrease the bioavailability of {v}",
"Difluocortolone"
]
]
] |
Alclofenac may increase the severity of adverse effects when combined with Clonixin and Clonixin may increase the severity of adverse effects when combined with Difluocortolone
Alclofenac may increase the neuroexcitatory activities of Gatifloxacin and Gatifloxacin may increase the severity of adverse effects when combined with Difluocortolone
Alclofenac may increase the severity of adverse effects when combined with Acemetacin and Acemetacin may increase the severity of adverse effects when combined with Difluocortolone
Alclofenac may increase the severity of adverse effects when combined with Estrone and Estrone may increase the serum concentration of Difluocortolone
Alclofenac may decrease the diuretic activities of Furosemide and Furosemide may increase the hypokalemic activities of Difluocortolone
Alclofenac may decrease the therapeutic efficacy of Polythiazide and Polythiazide may increase the hypokalemic activities of Difluocortolone
Alclofenac may increase the severity of adverse effects when combined with Clonixin and Clonixin may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Difluocortolone
Alclofenac may increase the severity of adverse effects when combined with Teriflunomide and Teriflunomide may decrease the serum concentration of Warfarin and Warfarin may increase the anticoagulant activities of Difluocortolone
Alclofenac may increase the neuroexcitatory activities of Gatifloxacin and Gatifloxacin may decrease the absorption and serum concentration of Tromethamine and Tromethamine can decrease the bioavailability of Difluocortolone
|
DB08798
|
DB00657
| 489 | 45 |
Sulfamoxole
|
Mecamylamine
|
Sulfamoxole is an antibacterial in the sulfonamide class.
|
A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
|
The risk or severity of adverse effects can be increased when Sulfamoxole is combined with Mecamylamine.
| 48 |
[
[
[
489,
71,
45
]
],
[
[
489,
1,
1516
],
[
1516,
71,
45
]
],
[
[
489,
155,
1528
],
[
1528,
71,
45
]
],
[
[
489,
69,
239
],
[
239,
71,
45
]
],
[
[
489,
69,
640
],
[
640,
82,
45
]
],
[
[
489,
1,
1516
],
[
1516,
155,
1528
],
[
1528,
71,
45
]
],
[
[
489,
155,
1528
],
[
1528,
1,
1516
],
[
1516,
71,
45
]
],
[
[
489,
1,
1518
],
[
1518,
7,
4142
],
[
4142,
161,
45
]
],
[
[
489,
1,
1536
],
[
1536,
1,
1516
],
[
1516,
71,
45
]
],
[
[
489,
155,
1538
],
[
1538,
7,
5249
],
[
5249,
161,
45
]
]
] |
[
[
[
"Sulfamoxole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} (Compound) resembles {v} (Compound)",
"Silver sulfadiazine"
],
[
"Silver sulfadiazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfacetamide"
],
[
"Sulfacetamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} may decrease the metabolism of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} may decrease the metabolism of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the hypotensive activities of {v}",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} (Compound) resembles {v} (Compound)",
"Silver sulfadiazine"
],
[
"Silver sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfacetamide"
],
[
"Sulfacetamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfacetamide"
],
[
"Sulfacetamide",
"{u} (Compound) resembles {v} (Compound)",
"Silver sulfadiazine"
],
[
"Silver sulfadiazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadimethoxine"
],
[
"Sulfadimethoxine",
"{u} (Compound) upregulates {v} (Gene)",
"NNT"
],
[
"NNT",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfathiazole"
],
[
"Sulfathiazole",
"{u} (Compound) resembles {v} (Compound)",
"Silver sulfadiazine"
],
[
"Silver sulfadiazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
]
],
[
[
"Sulfamoxole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethizole"
],
[
"Sulfamethizole",
"{u} (Compound) upregulates {v} (Gene)",
"PROS1"
],
[
"PROS1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mecamylamine"
]
]
] |
Sulfamoxole (Compound) resembles Silver sulfadiazine (Compound) and Silver sulfadiazine may increase the severity of adverse effects when combined with Mecamylamine
Sulfamoxole (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide may increase the severity of adverse effects when combined with Mecamylamine
Sulfamoxole may decrease the metabolism of Valsartan and Valsartan may increase the severity of adverse effects when combined with Mecamylamine
Sulfamoxole may decrease the metabolism of Quinine and Quinine may increase the hypotensive activities of Mecamylamine
Sulfamoxole (Compound) resembles Silver sulfadiazine (Compound) and Silver sulfadiazine (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide may increase the severity of adverse effects when combined with Mecamylamine
Sulfamoxole (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Silver sulfadiazine (Compound) and Silver sulfadiazine may increase the severity of adverse effects when combined with Mecamylamine
Sulfamoxole (Compound) resembles Sulfadimethoxine (Compound) and Sulfadimethoxine (Compound) upregulates NNT (Gene) and NNT (Gene) is upregulated by Mecamylamine (Compound)
Sulfamoxole (Compound) resembles Sulfathiazole (Compound) and Sulfathiazole (Compound) resembles Silver sulfadiazine (Compound) and Silver sulfadiazine may increase the severity of adverse effects when combined with Mecamylamine
Sulfamoxole (Compound) resembles Sulfamethizole (Compound) and Sulfamethizole (Compound) upregulates PROS1 (Gene) and PROS1 (Gene) is upregulated by Mecamylamine (Compound)
|
DB00252
|
DB08992
| 142 | 220 |
Phenytoin
|
Eperisone
|
Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market.
|
Eperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.
|
The serum concentration of Eperisone can be increased when it is combined with Phenytoin.
| 72 |
[
[
[
142,
95,
220
]
],
[
[
142,
71,
949
],
[
949,
155,
220
]
],
[
[
142,
137,
194
],
[
194,
26,
220
]
],
[
[
142,
192,
164
],
[
164,
26,
220
]
],
[
[
142,
225,
197
],
[
197,
26,
220
]
],
[
[
142,
180,
171
],
[
171,
26,
220
]
],
[
[
142,
26,
528
],
[
528,
223,
220
]
],
[
[
142,
97,
581
],
[
581,
225,
220
]
],
[
[
142,
95,
236
],
[
236,
71,
220
]
],
[
[
142,
33,
539
],
[
539,
71,
220
]
]
] |
[
[
[
"Phenytoin",
"{u} may increase the serum concentration of {v}",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} (Compound) resembles {v} (Compound)",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound) and {u} can increase the metabolism of {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} can increase the metabolism of {v}",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} can increase the metabolism of {v}",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Telithromycin"
],
[
"Telithromycin",
"{u} may decrease the metabolism of {v}",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} may decrease the serum concentration of {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} may increase the serum concentration of {v}",
"Salicylic acid"
],
[
"Salicylic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Eperisone"
]
],
[
[
"Phenytoin",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the severity of adverse effects when combined with {v}",
"Eperisone"
]
]
] |
Phenytoin may increase the severity of adverse effects when combined with Triprolidine and Triprolidine (Compound) resembles Eperisone (Compound)
Phenytoin (Compound) resembles Methylphenobarbital (Compound) and Phenytoin can increase the metabolism of Methylphenobarbital and Methylphenobarbital can increase the metabolism of Eperisone
Phenytoin may increase the central nervous system depressant activities of Phenobarbital and Phenobarbital can increase the metabolism of Eperisone
Phenytoin may increase the severity of adverse effects when combined with Amobarbital and Amobarbital can increase the metabolism of Eperisone
Phenytoin can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Eperisone
Phenytoin can increase the metabolism of Telithromycin and Telithromycin may decrease the metabolism of Eperisone
Phenytoin may decrease the serum concentration of Rosuvastatin and Rosuvastatin may increase the severity of adverse effects when combined with Eperisone
Phenytoin may increase the serum concentration of Salicylic acid and Salicylic acid may increase the severity of adverse effects when combined with Eperisone
Phenytoin may reduce the serum concentration of the active metabolites of Artemether and Artemether may increase the severity of adverse effects when combined with Eperisone
|
DB00835
|
DB01124
| 165 | 297 |
Brompheniramine
|
Tolbutamide
|
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
|
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
|
The metabolism of Tolbutamide can be decreased when combined with Brompheniramine.
| 46 |
[
[
[
165,
69,
297
]
],
[
[
165,
6,
7128
],
[
7128,
160,
297
]
],
[
[
165,
18,
14599
],
[
14599,
172,
297
]
],
[
[
165,
180,
177
],
[
177,
26,
297
]
],
[
[
165,
69,
429
],
[
429,
26,
297
]
],
[
[
165,
69,
1037
],
[
1037,
185,
297
]
],
[
[
165,
225,
911
],
[
911,
185,
297
]
],
[
[
165,
71,
193
],
[
193,
185,
297
]
],
[
[
165,
249,
576
],
[
576,
185,
297
]
],
[
[
165,
69,
266
],
[
266,
223,
297
]
]
] |
[
[
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} can increase the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the hypoglycemic activities of {v}",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the hypoglycemic activities of {v}",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may increase the hypoglycemic activities of {v}",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the hypoglycemic activities of {v}",
"Tolbutamide"
]
],
[
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
]
]
] |
Brompheniramine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tolbutamide (Compound)
Brompheniramine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Tolbutamide (Compound)
Brompheniramine can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Tolbutamide
Brompheniramine may decrease the metabolism of Lopinavir and Lopinavir can increase the metabolism of Tolbutamide
Brompheniramine may decrease the metabolism of Betaxolol and Betaxolol may increase the hypoglycemic activities of Tolbutamide
Brompheniramine may increase the severity of adverse effects when combined with Oxprenolol and Oxprenolol may increase the hypoglycemic activities of Tolbutamide
Brompheniramine may increase the severity of adverse effects when combined with Levomilnacipran and Levomilnacipran may increase the hypoglycemic activities of Tolbutamide
Brompheniramine may increase the serum concentration of Metoprolol and Metoprolol may increase the hypoglycemic activities of Tolbutamide
Brompheniramine may decrease the metabolism of Indinavir and Indinavir may decrease the metabolism of Tolbutamide
|
DB00401
|
DB01029
| 512 | 535 |
Nisoldipine
|
Irbesartan
|
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
|
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459] Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459]
|
The risk or severity of adverse effects can be increased when Nisoldipine is combined with Irbesartan.
| 48 |
[
[
[
512,
71,
535
]
],
[
[
512,
71,
304
],
[
304,
71,
535
]
],
[
[
512,
71,
567
],
[
567,
1,
535
]
],
[
[
512,
5,
17090
],
[
17090,
159,
535
]
],
[
[
512,
6,
4590
],
[
4590,
160,
535
]
],
[
[
512,
21,
28395
],
[
28395,
175,
535
]
],
[
[
512,
95,
191
],
[
191,
26,
535
]
],
[
[
512,
288,
177
],
[
177,
26,
535
]
],
[
[
512,
249,
150
],
[
150,
26,
535
]
],
[
[
512,
180,
164
],
[
164,
26,
535
]
]
] |
[
[
[
"Nisoldipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Candesartan cilexetil"
],
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} can increase the metabolism of {v}",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} can increase the metabolism of {v} and {u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} may increase the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Irbesartan"
]
],
[
[
"Nisoldipine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Irbesartan"
]
]
] |
Nisoldipine may increase the severity of adverse effects when combined with Candesartan cilexetil and Candesartan cilexetil may increase the severity of adverse effects when combined with Irbesartan
Nisoldipine may increase the severity of adverse effects when combined with Losartan and Losartan (Compound) resembles Irbesartan (Compound)
Nisoldipine (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Irbesartan (Compound)
Nisoldipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Irbesartan (Compound)
Nisoldipine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Irbesartan (Compound)
Nisoldipine may increase the serum concentration of Aprepitant and Aprepitant can increase the metabolism of Irbesartan
Nisoldipine can increase the metabolism of Rifapentine and Nisoldipine may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Irbesartan
Nisoldipine may increase the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Irbesartan
Nisoldipine can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Irbesartan
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.